

## (19) World Intellectual Property Organization International Bureau

(43) International Publication Date  
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number  
WO 2004/007743 A2

(51) International Patent Classification<sup>7</sup>: C12Q (74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(21) International Application Number: PCT/IB2003/003727 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 17 July 2003 (17.07.2003)

(25) Filing Language: English (26) Publication Language: English

(30) Priority Data: 60/396,432 17 July 2002 (17.07.2002) US

(71) Applicant: COLEY PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Selbert-Strasse 9, 40764 Langenfeld (DE).

(72) Inventors; and (75) Inventors/Applicants (for US only): WAGNER, Hermann [DE/DE]; Kaagangerstrasse 36, 82279 Eching (DE). KRETZSCHMAR, Hans [DE/DE]; Nelkenweg 5a, 82515 Wolfratshausen (DE). SETHI, Shneh [DE/DE]; Platanen Strasse 56, 81377 Muenchen (DE).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/007743 A2

(54) Title: USE OF CPG NUCLEIC ACIDS IN PRION-DISEASE

(57) Abstract: Methods are provided which are useful in the treatment of prion diseases and other protein deposit diseases, including, for example, post-exposure prophylaxis against the development of iatrogenic Creutzfeldt-Jakob disease. The methods involve the use of immunostimulatory nucleic acids, including CpG nucleic acids.

- 1 -

## USE OF CpG NUCLEIC ACIDS IN PRION DISEASE

### Field of the Invention

The instant invention pertains to methods useful in the treatment of prion diseases, including, for example, post-exposure prophylaxis against the development of iatrogenic Creutzfeldt-Jakob disease. The methods involve the use of immunostimulatory nucleic acids.

### Background of the Invention

Prion diseases include a number of fatal, neurodegenerative diseases believed to be caused by aggregates of normal protein that is present in an abnormal conformation. The normal protein, prion protein, is usually present in the cell membrane of many tissues, particularly neuronal tissue. The abnormally conformed prion protein is believed to be directly involved in converting normally conformed prion protein into more of the abnormally conformed prion protein, which then self-assembles into aggregates that are damaging to neuronal tissue anatomy and function.

At least some of the prion diseases are transmissible. However, unlike bacteria, viruses, fungi, parasites, and other replicating pathogens, transmissible prions are simply proteins; they are transmissible without any accompanying nucleic acid. For reasons that are not yet fully understood, the abnormally conformed prion proteins normally do not induce an immune response. Thus, exposure of a healthy individual to abnormally conformed prion protein can initiate a prion disease that can go unchecked by the immune system.

Exposure to abnormally conformed prion protein thus represents a health risk to susceptible individuals. Such individuals include humans and non-humans, principally cows and sheep. Exposure can come about through contact with prion-diseased animal products through ingestion, iatrogenic or work-related exposure, transplantation, and administration of pharmaceutical preparations.

### Summary of the Invention

The instant invention is based in part on the unexpected discovery by the inventors that administration of immunostimulatory nucleic acid to a subject that is exposed to abnormally conformed prion protein is an effective treatment of prion disease. The immunostimulatory nucleic acid effectively delayed and even prevented disease in animals

- 2 -

administered very large doses of prion-diseased brain homogenates that uniformly caused fatal disease in all untreated control animals similarly exposed to prion-diseased brain homogenates.

The immunostimulatory nucleic acids are useful in the treatment of prion diseases, including Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE), and scrapie. The methods of the invention are also useful for the study of these diseases, for instance, in animal models. The methods will also be useful for developing an understanding of how prion proteins normally fail to elicit an immune response and how an immune response can be elicited and used to treat prion protein disease.

The immunostimulatory nucleic acids are also useful in the treatment of other neurologic diseases involving abnormal protein deposits or aggregates. Such diseases include Alzheimer's disease, which involves deposits of amyloid. The main component of amyloid plaques is amyloid- $\beta$  peptide (A $\beta$ ), a fibrillar 40-42 amino acid peptide that accumulates extracellularly and causes neuronal death.

In one aspect the invention provides a method for treating a prion disease in a subject. The method involves administering to a subject having or at risk of developing a prion disease a CpG nucleic acid in an effective amount to treat the prion disease. In one embodiment the administering follows exposure of the subject to a prion protein that is associated with a prion disease. In one embodiment the prion disease is a transmissible spongiform encephalopathy (TSE). In one embodiment the subject is a human.

In various preferred embodiments, the prion disease is scrapie, BSE, or a form of CJD. The CJD in one embodiment is iatrogenic CJD (iCJD). In another embodiment the CJD is variant CJD (vCJD). In yet another embodiment the CJD is sporadic CJD.

In one aspect the invention provides a method for inducing an immune response to a prion protein. The method according to this aspect of the invention involves the steps of contacting an antigen-presenting cell (APC) with a prion protein and contacting the APC with a CpG nucleic acid in an effective amount to induce an immune response to the prion protein. In one embodiment the immune response occurs *in vivo*. In one embodiment the immune response occurs *in vitro*. In all embodiments according to this aspect of the invention the APC is preferably chosen from a B cell, a dendritic cell, a macrophage, and a monocyte. In one preferred embodiment the APC is a dendritic cell.

- 3 -

Also according to this aspect of the invention, in one embodiment the APC expresses a Toll-like receptor (TLR) that signals in response to the CpG nucleic acid. It has recently been reported that CpG nucleic acid can specifically induce a particular TLR, designated TLR9, to signal. Accordingly, in one embodiment the TLR is TLR9.

In one embodiment the prion protein includes prion protein:scrapie form (PrP<sup>Sc</sup>). In another embodiment the prion protein includes a fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup>. In yet another embodiment the prion protein includes a derivative of PrP<sup>Sc</sup> or a derivative of a fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup>.

In one embodiment the prion protein is prion protein:scrapie form (PrP<sup>Sc</sup>). In another embodiment the prion protein is a fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup>. In yet another embodiment the prion protein is a derivative of PrP<sup>Sc</sup> or a derivative of a fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup>.

It has been reported that certain CpG nucleic acids are more effective in one species than in another. Accordingly, in preferred embodiments the CpG nucleic acid is optimized for use in a species of the subject.

It has also been reported that CpG nucleic acids appear to fall into different classes based on certain structural features as well as their function. At least three classes are believed to exist, denoted Class A, Class B, and Class C. In one embodiment the CpG nucleic acid is a class B CpG nucleic acid. In one embodiment the CpG nucleic acid is a class A CpG nucleic acid. In one embodiment the CpG nucleic acid is a class C CpG nucleic acid.

These and other features of the invention are described in greater detail in connection with the detailed description of the invention.

### **Detailed Description of the Invention**

A major step in the study of prions and the diseases that they cause was the discovery and purification of a protein designated prion protein (PrP). Bolton et al. (1982) *Science* 218:1309-11; Prusiner SB et al. (1982) *Biochemistry* 21:6942-50; McKinley MP et al. (1983) *Cell* 35:57-62. Complete prion protein-encoding genes have since been cloned, sequenced and expressed in transgenic animals. PrP<sup>C</sup> is encoded by a single-copy host gene (Basler K et

- 4 -

al. (1986) *Cell* 46:417-28) and is normally found at the outer surface of neurons. Prion diseases are accompanied by the conversion of PrP<sup>C</sup> into a modified form called PrP<sup>Sc</sup>.

The scrapie isoform of the prion protein (PrP<sup>Sc</sup>) is thought necessary for both the transmission and pathogenesis of the transmissible neurodegenerative diseases of animals and humans. See Prusiner SB (1991) *Science* 252:1515-22. The most common prion diseases of animals are scrapie of sheep and goats and bovine spongiform encephalopathy (BSE; "mad cow disease") of cattle. Wilesmith J et al. (1991) *Microbiol Immunol* 172:21-38. Four prion diseases of humans have been identified: (1) kuru, (2) Creutzfeldt-Jakob disease (CJD), (3) Gerstmann-Sträussler-Scheinker (GSS) syndrome, and (4) fatal familial insomnia. Gajdusek DC (1977) *Science* 197:943-60; Medori et al. (1992) *N Engl J Med* 326:444-9.

Most CJD cases are sporadic, but about 10-15% are inherited as autosomal dominant disorders that are caused by mutations in the human PrP gene. Hsiao et al. (1990) *Neurology* 40:1820-7; Goldfarb et al. (1992) *Science* 258:806-8. Iatrogenic CJD has been caused by human growth hormone derived from cadaveric pituitaries as well as dura mater grafts. Brown et al. (1992) *Lancet* 340:24-7. Despite numerous attempts to link CJD to an infectious source such as the consumption of meat from scrapie-infected sheep, none has been identified to date (Harries-Jones et al. (1988) *J Neurol Neurosurg Psychiatry* 51:1113-9) except in cases of iatrogenically induced disease. On the other hand, kuru, which for many decades devastated the Fore and neighboring tribes of the New Guinea highlands, is believed to have been spread by infection during ritualistic cannibalism.

The major component of purified infectious prions, designated PrP 27-30, is the proteinase K resistant core of a larger native protein PrP<sup>Sc</sup> which is the disease causing form of the ubiquitous cellular protein PrP<sup>C</sup>. PrP<sup>Sc</sup> is found only in scrapie infected cells, whereas PrP<sup>C</sup> is present in both infected and uninfected cells implicating PrP<sup>Sc</sup> as the major, if not the sole, component of infectious prion particles. Since both PrP<sup>C</sup> and PrP<sup>Sc</sup> are encoded by the same single copy gene, great effort has been directed toward unraveling the mechanism by which PrP<sup>Sc</sup> is derived from PrP<sup>C</sup>. Central to this goal has been the characterization of physical and chemical differences between these two molecules. Properties distinguishing PrP<sup>Sc</sup> from PrP<sup>C</sup> include low solubility (Meyer RK et al. (1986) *Proc Natl Acad Sci USA* 83:2310-4), poor antigenicity (Kascak RJ et al. (1987) *J Virol* 61:3688-93; Serban D et al. (1990) *Neurology* 40:110-7), protease resistance (Oesch B et al. (1985) *Cell* 40:735-46), and polymerization of PrP 27-30 into rod-shaped aggregates which are very similar, on the

- 5 -

ultrastructural and histochemical levels, to the PrP amyloid plaques seen in scrapie-diseased brains (Prusiner SB et al. (1983) *Cell* 35(2 Pt 1):349-58). By using proteinase K it is possible to denature PrP<sup>C</sup> but not PrP<sup>Sc</sup>. To date, attempts to identify any post-translational chemical modifications in PrP<sup>C</sup> that lead to its conversion to PrP<sup>Sc</sup> have proven fruitless. Stahl N et al. (1993) *Biochemistry* 31:5043-53. Consequently, it has been proposed that PrP<sup>C</sup> and PrP<sup>Sc</sup> are in fact conformational isomers of the same molecule.

Conformational description of PrP using conventional techniques has been hindered by problems of solubility and the difficulty in producing sufficient quantities of pure protein. However, PrP<sup>C</sup> and PrP<sup>Sc</sup> are conformationally distinct. Theoretical calculations based upon the amino acid sequences of PrPs from several species have predicted four putative helical motifs in the molecule. Experimental spectroscopic data would indicate that in PrP<sup>C</sup> these regions adopt alpha-helical arrangements, with virtually no beta-sheet. Pan et al. (1993) *Proc Natl Acad Sci USA* 90:10962-6). In dramatic contrast, in the same study it was found that PrP<sup>Sc</sup> and PrP 27-30 possess significant beta-sheet content, which is typical of amyloid proteins. Moreover, studies with extended synthetic peptides, corresponding to PrP amino acid residues 90-145, have demonstrated that these truncated molecules may be converted to either alpha-helical or beta-sheet structures by altering their solution conditions. The transition of PrP<sup>C</sup> to PrP<sup>Sc</sup> requires the adoption of beta-sheet structure by regions that were previously alpha-helical.

In general, scrapie infection fails to produce an immune response, with host organisms being tolerant to PrP<sup>Sc</sup> from the same species. Polyclonal anti-PrP antibodies have been raised in rabbits following immunization with large amounts of Syrian hamster PrP 27-30. Bendheim PE et al. (1985) *Proc Natl Acad Sci USA* 82:997-1001; Bode L et al. (1985) *J Gen Virol* 66:2471-8. Similarly, a handful of anti-PrP monoclonal antibodies have been produced in mice. Kascsak RJ et al. (1987) *J Virol* 61:3688-93; Barry RA et al. (1986) *J Infect Dis* 154:518-21. These antibodies are able to recognize native PrP<sup>C</sup> and denatured PrP<sup>Sc</sup> from both Syrian hamsters and humans equally well, but do not bind to murine PrP. Unsurprisingly, the epitopes of these antibodies were mapped to regions of sequence containing amino acid differences between Syrian hamster and murine PrP. Rogers et al. (1991) *J Immunol* 147:3568-74.

The DNA sequence of the human, sheep and cow PrP genes have been determined, allowing, in each case, the prediction of the complete amino acid sequence of their respective

- 6 -

PrP proteins. The normal amino acid sequence which occurs in the vast majority of individuals is referred to as the wild-type PrP sequence. This wild-type sequence is subject to certain characteristic polymorphic variations. In the case of human PrP, two polymorphic amino acids occur at residues 129 (Met/Val) and 219 (Glu/Lys). Sheep PrP has two amino acid polymorphisms at residues 136 and 171, while bovine PrP has either five or six repeats of an eight amino acid motif sequence (octarepeats) in the amino terminal region of the mature prion protein. While none of these polymorphisms are of themselves pathogenic, they appear to influence prion diseases. Distinct from these normal variations of the wild-type PrP proteins, certain mutations of the human PrP gene which alter either specific amino acid residues of PrP or the number of octarepeats have been identified which segregate with inherited human prion diseases.

For example, sequences of chicken, bovine, sheep, rat, and mouse PrP genes are disclosed and published within Gabriel JM et al. (1992) *Proc Natl Acad Sci USA* 89:9097-101. A sequence for a PrP gene of Syrian hamster is published in Basler K et al. (1986) *Cell* 46:417-28. A PrP gene of sheep is published by Goldmann W et al. (1990) *Proc Natl Acad Sci USA* 87:2476-80. A gene sequence for bovine PrP is published in Goldmann W et al. (1991) *J Gen Virol* 72:201-4. A sequence for chicken PrP gene is published in Harris DA et al. (1991) *Proc Natl Acad Sci USA* 88:7664-8. A PrP gene sequence for mink is published in Kretzschmar HA et al. (1992) *J Gen Virol* 73:2757-61. A human PrP gene sequence is published in Kretzschmar HA et al. (1986) *DNA* 5:315-24. A PrP gene sequence for mouse is published in Locht C et al. (1986) *Proc Natl Acad Sci USA* 83:6372-6. A PrP gene sequence for sheep is published in Westaway D et al. (1994) *Genes Dev* 8:959-69. These publications are all incorporated herein by reference to disclose and describe the PrP gene and PrP amino acid sequences.

Human PrP cDNA (SEQ ID NO:1; GenBank Accession No. M13899)

cgccgcgcgcg	agtttctcct	ctcctcacga	ccgaggcaga	gcagtcatta	tggcgaacct	60
tggctgctgg	atgctggttc	tctttgtggc	cacatggagt	gacctgggcc	tctgcaagaa	120
gcgcggcaag	cctggaggat	ggaacactgg	gggcagccga	tacccggggc	agggcagccc	180
tggaggcaac	cgctaccac	ctcagggcgg	ttgtggctgg	gggcagcctc	atggtgtgtgg	240
ctgggggcag	cctcatggtg	gtggctgggg	gcagccccat	ggtggtggct	ggggacagcc	300
tcatgggtt	ggctggggtc	aaggagggtgg	cacccacagt	cagtggaaaca	agccgagtaa	360
gcaaaaaacc	aacatgaagc	acatggctgg	tgctgcagca	gctggggcag	tgtggggggg	420
ccttggcggc	tacatgctgg	gaagtgcacat	gagcaggccc	atcatacatt	tccgcagtga	480
ctatgaggac	cgttactatc	gtgaaaacat	gcaccgttac	cccaaccaag	tgtactacag	540
gccccatggat	gagtacagca	accagaacaa	ctttgtgcac	gactgcgtca	atatcacaat	600
caagcagcac	acggtcacca	caaccaccaa	gggggagaac	ttcaccgaga	ccgacgttaa	660
gatgatggag	cgcgtgggtg	agcagatgtg	tatcaccagg	tacgagaggg	aatctcaggc	720

- 7 -

ctattaccag	agaggatcga	gcatggtcct	cttctcctct	ccacctgtga	tcctcctgat	780
ctcttcctc	atcttcctga	tagtggatg	aggaaggct	tcctgtttc	accatcttc	840
taatctttt	ccagcttgag	ggaggcggta	tccacctgca	gcccttttag	tggtggtgtc	900
tcactcttc	ttctctctt	gtcccgata	ggctaatcaa	tacccttgc	actgatggc	960
actggaaaac	atagagtata	cctgagatgc	tggtaagcc	cccttgatt	gagttcatca	1020
tgagccgtt	ctaattgcac	gccagtaaaa	gtataacagc	aaataaccat	tggtaatct	1080
ggacttattt	ttggacttag	tgcaacaggt	tgaggctaaa	acaatctca	gaacagtctg	1140
aaatacctt	gcctggatac	ctctggctcc	ttcagcagct	agagctcagt	atactaattgc	1200
cctatcttag	tagagattt	atagctattt	agagatattt	tccatTTaa	gaaaaccccga	1260
caacattct	gccaggttt	ttaggaggcc	acatgatact	tattcaaaaa	aatcctagag	1320
attcttagct	cttggatgc	aggctcagcc	cgctggagca	tgagctctgt	gtgtaccgag	1380
aactgggtt	atgtttact	tttacagta	tgggctacac	agcagctgtt	caacaagagt	1440
aaatattgtc	acaacactga	acctctggct	agaggacata	ttcacagtga	acataactgt	1500
aacatataat	aaaggcttct	gggacttgaa	atcaaatgtt	tgggaatgtt	gcccttggag	1560
gcaacccccc	atTTtagat	ttttaaggac	cctatatgtg	gcattcctt	ctttaaacta	1620
taggttaat	aggcagctga	aaagtaaaat	gccttctaga	cactgaaggc	aaatctcctt	1680
tgtccattt	cctggaaacc	agaatgattt	tgacatacag	gagagctgca	gttgtgaaag	1740
caccatcatc	atagaggatg	atgttaattt	aaaatggtca	gtgtgcaaag	aaaagaactg	1800
cttgcattt	tttattttctg	tctcataatt	gtcaaaaaacc	agaatttagt	caagttcata	1860
gtttctgtt	ttggctttt	aatcaaagaa	tagggagaca	atctaaaaaa	tatcttaggt	1920
tggagatgac	agaaatatga	ttgatttga	gtggaaaaaaag	aaattctgtt	aatgttaatt	1980
aaagtaaaat	tattccctga	attgtttgat	attgtcacct	agcagatatg	tattactttt	2040
ctgcaatgtt	attattggct	tgcactttgt	gagtatctat	gtaaaaatat	atatgtatat	2100
aaaatataat	ttgcataatgg	cagacttagg	agttttgttt	agagcagttt	acatctgaag	2160
tgtctaatgc	attaactttt	gtaaggtact	gaataacttaa	tatgtggaa	acccttttgc	2220
gtggcctta	ggcttacaat	gtgcactgaa	tcgtttcatg	taagaatcca	aagtggacac	2280
cattaacagg	tctttaaat	atgcataatgt	tttataatttt	ctatattttt	aactttgcat	2340
gttcttctgtt	tgttatataa	aaaaattgtt	aatgtttat	atctgactga	aattaaacga	2400
gcgaagatga	gcacc					2415

**Mink PrP genomic DNA (SEQ ID NO:2; GenBank Accession No. S46825)**

tcattttgtt	ttgtttgtt	ttgtttcag	ataagccatc	atggtaaaa	gccacatagg	60
cagctggctc	ctgggtctct	ttgtggccac	atggagtgac	attggcttc	gcaagaagcg	120
gccaaggct	ggaggaggt	ggaacactgg	ggggagccga	tacccaggc	agggcagtc	180
tggaggcaac	cgctaccac	cccagggtgg	ttggcgctgg	ggccagcccc	acgggggtgg	240
ctggggacag	ccccacgggg	gtggctgggg	ttagccccac	gggggtggct	ggggacagcc	300
gcatggtgcc	ggtggctgg	gtcaagggtgg	ttggagccac	ggtcagttgg	gcaagccca	360
taagccaaa	accaacatga	agcatgtggc	gggagccgca	gcagccgggg	cggtcggtgg	420
gggcctgggc	ggctacatgc	ttggggagcgc	catgagcagg	cccctcattc	attttggcaa	480
cgactatgag	gaccgtact	accgtgagaa	catgtaccgc	taccccaacc	aagtgtacta	540
caagccggtg	gatcgtaca	gcaaccagaa	caacttcgt	catgactgc	tcaacatcac	600
ggtcaagcag	cacacgggt	ccaccaccac	caagggcgg	aacttcacgg	agaccgacat	660
gaagatcatg	gagcgcgtgg	tggagcagat	gtgtgtcacc	cagtaccagc	gagagtccga	720
ggcttactac	cagaggggggg	cgagcgcac	cctttctcg	ccccctcccg	tgatccttc	780
cattcactg	ctcattctcc	tgtatgtgg	atgaggatgg	cettccatt	cttcctatcg	840
tcttcaccc	ttacagggtt	ggggaggggg	tgtctaccta	cagccctgt	gtgggtgggt	900
ctcattctcg	tttctcttta	tcacccatag	gtaatcccc	ttggccctga	tggccctggg	960
aaatgttagag	cagacccagg	atgctattta	tcacagcccc	catgtgttgg	agtccttcag	1020
gggccaatgc	tagtgcagg	ctgagaataa	cagcaaatca	tcattgttgg	acctagggt	1080
gctttttgt	tgttgtgtc	tagtgcagct	gaccgaggct	aaaacaattc	tcaaaacagt	1140
tttcaaatac	ctttgcctgg	aaacctctgg	ctcctgtgc	agcttagagct	cagtacatta	1200
atgtcccatc	ttagccgtt	tttcatacgca	acttggggaa	gttttctcc	ccactctaaa	1260
agaacgcgt	tgcacttccc	tgtgcaaaaga	acatttctgc	caaatttggaa	agaggccac	1320
atgatattca	ttcaaaaac	aaaactagaa	accctttgt	cttggacgc	agcccgcc	1380
gctaggagca	ccaaaactgg	gcgatggtt	gcattctgc	gctgtggct	tgcggcagcc	1440
gaggtgtcca	gcgttaaatat	tgatgcacg	ctagacctag	gcagaggatg	tttgcacagg	1500
gaatgaacat	aatcaacagt	gcgaaaatgc	tacaaaaat	cccacactgg	ggagcagtgt	1560
ccttggaggc	aagttttttt	cctttggga	catttaaagc	cccttatatgt	ggcattcctt	1620

- 8 -

tctttcgtaa cctaaactat agataattaa ggcagttaaa aattgaactt ccttccaggc 1680  
 cccaaagagca aatctttgtt cacttacctg gaaaccagaa tgatttgac acagaggaag 1740  
 gtgcagctgt taaaataacc ctcacccctag aagattgcat catggagaaa acgatccgta 1800  
 gacaaaaatg atcgcatttc ttcattgctg tctcgtaatt gacagaaacc agaattatgt 1860  
 caagtcctag tttctataat cagctttga atcaaagaat ggaagtccat ccaaaaaaaaa 1920  
 aaaagaaata ccttaggtca cccatgacag aaatacccat tcaggttaga aaaaaggaat 1980  
 tctgttaact gttatTTAAG taaggcaaaa ttattgtccg gattgttgc tatcatcagc 2040  
 tagcagataa attagcattc tgcaatgttc ccggcttgcg ctgtcggtt atttgatgtt 2100  
 aaaaaaaaaatt attatataat ttgtgtatga ccaaacttaga agttttgtt agaggagtt 2160  
 acatctgata tatctaattgc accaccagtt ttggaaaggta ctaaatactt aatatgtaga 2220  
 aatccttttg cgtggccctc aggcttacac gtgcactgaa tagtttgtt tgatagagcc 2280  
 catgtggct tcgaaatatg catgtacttt atatTTCTA tatttgcac tgggcatgt 2340  
 cttgtataaa aaatgtataa acattcgaac tcttgacttag aattaaacag gaactgagtg 2400  
 tgtcccatgt gtttgcagtg acattcacca ccgcaccctg tgggg 2446

**Syrian Hamster PrP cDNA (SEQ ID NO:3; GenBank Accession No. M14054)**

tcgaaaaatct	ccctcttttag	caatttcttg	ctccttagt	ttcagcaatt	gctttctcgc	60
tccatttaggc	aacctttcat	tttctcacct	ccccattat	gtaacgggag	caatgggttc	120
tggaccagtc	ttccattaaa	gatgatTTT	atagtcgggt	agcgcgtca	gggagtgatg	180
acacctgggg	gcggtttaaa	ccgtacaaatc	ccttaaacc	gtctggagcg	gtgactcatt	240
tccccaggga	gaagtggcgc	ggccattgg	gagcacga	caagccccgc	cccacccagc	300
ccggccccgc	cctgctaccc	ctcctgactc	actgccccgc	ccgcctcccc	ggggcggtccg	360
agcagcagac	cgagaaggca	catecgatcc	actcgatcg	tcgggtggcag	gtaagcggt	420
tctgaaggct	ggggccggga	aggggtctgg	agccaggcc	cggtaa	tcggcttccc	480
agagccaagc	ccggcttact	ccggctctcg	gggcgtcg	gcccggggc	tgaggttgag	540
tctggctggg	aggtgaccgc	gcacccgcag	ccgcgtct	ccttgcagg	ccgaacccca	600
ggagaggc	ggagccatcc	tttccccc	agccggctc	accccccag	tcgctcg	660
atggggatg	ggggatgggg	tggcatctt	tgactgtcg	ttgctt	cttctctt	720
tgtaatagct	acagcgaaca	taatTTTacc	cagggttcca	ccgtggc	gtccgtc	780
ggcatctctc	agtccagtagc	atacccaagg				810

**Sheep PrP cDNA (SEQ ID NO:4; GenBank Accession No. AJ223072)**

atgggtaaaa	gccacatagg	cagtggatc	ctgggtctct	ttgtgccc	atgtggatgac	60
gtgggcctct	gcaagaagcg	accaaaac	ggcggaggat	ggaacactgg	ggggagccga	120
tacccgggac	agggcagtcc	tggaggca	cgctatcc	ctcagg	gggtggctgg	180
ggtcagcccc	atggaggtgg	ctggggccaa	cctcatgg	gtggctgggg	tcagccccat	240
ggtggctggc	ggggacagcc	acatgggt	ggaggctgg	gtcaagg	ttggat	300
cagtggaa	agcccaat	gccaat	aatatgt	atgtggc	aggctgt	360
gctggagc	ttggatgggg	cttgg	tacatgt	gaagtgc	catgaggcc	420
cttatacatt	ttggcaat	ctatgagg	cgttactatc	gtgaa	acatgttac	480
cccaacca	tgtactac	accagtgg	cagtat	accaga	acccat	540
gactgtgt	acatcac	caagca	acagtcc	ccacc	ggggaga	600
ttcacccgaa	ctgacat	gataatgg	cgagtgg	agcaat	atcacc	660
taccagag	aatcccag	ttattac	aggggg	gtgtgat	ctttctt	720
cctctgt	tcctctcat	ctctt	attttct	taggata	ggggcaac	780
tcctgtt	attatctt	taatctt	cagg	ggggatgt	ctac	840
ccctgtat	gtgggtctc	atttctt	tctctt	tac	ttgtata	900
tggccttac	agcactgg	aatgaca	agacat	tgctt	tcaagt	960
ttagctc	attcta	ccat	cagt	atgtt	tctcattt	1020
ttcaaga	cctgacta	tttcc	ggaa	tgat	ccat	1080
ggccacata	tattcatt	aaaaa	actggaa	tttagt	ccat	1140
tccaccct	tgagag	tgt	ctgc	agac	ccagg	1200
tttgagg	acatttgc	gtaa	acac	tatttgc	atcaag	1260
caac	ttatgg	gagg	cat	atcaag	gatatt	1320
ctgagact	aaaattcc	catatgg	agg	tgat	ttccat	1380
tatgtt	cac	tgat	ttt	acataa	tagata	1440
aggtac	at	ttt	ctg	acat	ttat	1500

- 9 -

Bovine PrP cDNA (SEQ ID NO:5; GenBank Accession No. X55882)

atggtaaaaa	gccacatagg	cagttggatc	ctgggtctct	ttgtggccat	gtggagtgac	60
gtgggcctct	gcaagaagcg	accaaaaact	ggaggaggat	ggaacactgg	ggggagccga	120
tacccaggac	aggcagttcc	tggaggcaac	cgttatccac	ctcaggggagg	gggtggctgg	180
ggtcagcccc	atggaggtgg	ctggggccag	cctcatggag	gtggctgggg	ccagccctat	240
ggaggtggct	ggggtcagcc	ccatgggtgt	ggctggggac	agccacatgg	ttggtgaggc	300
tggggtaaag	gtggtaccca	cggtcaatgg	aacaaaccca	gtaagccaaa	aaccaacatg	360
aagcatgtgg	caggagctgc	tgcaagctgga	gcagttgtag	ggggccttgg	tggctacatg	420
ctgggaagtg	ccatgagcag	gcctttata	cattttggca	gtgactatga	ggaccgttac	480
tatcgtaaaa	acatgcaccc	ttaccccaac	caagtgtact	acaggccagt	ggatcagtat	540
agtaaccaga	acaacttgt	gcatgactgt	gtcaacatca	cagtcaaggg	acacacagtc	600
accaccacca	ccaagggggg	gaacttcacc	gaaactgaca	tcaagatgtat	ggagcgagtg	660
gtggagcaaa	tgtgcattac	ccagttaccag	agagaatccc	aggcttatta	ccaaacgaggg	720
gcaagtgtga	tccttttctc	ttcccttcct	gtgatctcc	tcatctctt	cctcattttt	780
ctcatagtag	gataag					795

- 10 -

## Chicken PrP cDNA (SEQ ID NO:6; GenBank Accession No. M61145)

gaattccctc	ggcagccagc	tcctccctct	cgctatttat	tccttctcc	ccccccctacg	60
ctggatctgg	atcatctcaa	gccgagcggt	gacggcttct	tggatcgctc	atacataaaat	120
atctgtgagt	cagaggaagc	aaccaccgac	ccaaagacct	caccccgagc	catggctagg	180
ctccctacca	cctgctgcct	gctggccctg	ctgctcgccg	cctgcaccga	cgtcgccctc	240
tccaaagaagg	gcaaaggcaa	acccagtgg	gggggttggg	gcgcgggag	ccatcgccag	300
cccgctacc	cccggccagcc	gggctaccct	cataacccag	ggtacccca	taacccaggg	360
tacccccaaca	accctggcta	tcccataac	cccgctacc	cccagaaccc	tggctacccc	420
cataacccag	gttacccagg	ctgggtcaa	gctacaacc	atccagcg	aggaagttac	480
cacaaccaga	agccatggaa	acccccc当地	accaacttca	agcacgtgc	gggggcagca	540
gcggcgggt	ctgtggtggg	gggcttgggg	ggctacgcca	tggggcgcgt	tatgtcaggg	600
atgaactacc	acttcgatag	acccgatgag	taccgatgg	ggagtggagaa	ctcgccgcgt	660
tatcccaacc	gggttacta	ccgggattac	agcagcccc	tgccacagga	cgtcttcgtg	720
gcccattgt	ttaacatcac	agtactgag	tacagcattt	gcccgtgtc	caagaagaac	780
accccgagg	ctgtggcg	agcaaacc	acggaggtgg	agatggagaa	caaagtgg	840
acgaaggtga	tccgcgagat	gtgcgtgcag	cagtaccgcg	agtaccgcct	ggcctcggg	900
atccagctgc	accctgctga	cacccggctc	gcccgttcc	tcctccct	caccaccc	960
tttgcgtgc	actgtatgg	tgccgtccc	ggggccctgt	gcagtgagat	gacatcg	1020
ccccgtgccc	acccatgggg	tgttccctgt	cctcgcttt	gtccatctt	gttgaagat	1080
tcccccgcgt	gcctccccc	aggctgtat	tggggcaat	gggagggat	tttgcctgt	1140
cctggcgtg	gcaggacggc	tgctgggt	ggagtggtat	gccc	ttggccttac	1200
cacttccccc	tccttcct	ttctggggc	gagatatgg	ctcgcc	cottatttgc	1260
cctgcaagag	cgtatctgaa	aatccctt	gtaacaacc	agggttttac	ctaatctgt	1320
tagccccagt	gacagcagag	cgccttccc	cagggcacac	caacccca	ctgaggtgt	1380
tggagccac	acgtcccat	gaggctgtat	ggttttgggg	cgtrccaa	aacaccctgg	1440
gtactgagg	tgcaattgt	gctctttaat	ctgccaatcc	caaccc	tttgcgtat	1500
gaactgcctg	ctctgcattt	tgcatgctc	aaacaccc	tgccgcagc	ccccccaaat	1560
agagtgattt	gggatagtg	aggctga	cacagcag	tggattgg	ctcatcat	1620
caatccatga	tgctttgtt	ccagctg	ctca	ttttatagcc	tgcccagagg	1680
aaggagcgc	tgctaaatgc	ccaaaagg	aacactgag	aaaagctt	ttaatgtat	1740
gatagagaac	gagtgcattt	cgcacagatc	agccatgg	gcatcg	tttgcgtat	1800
caaaaacccaa	aggatgctaa	aatgcagcc	aagggaatc	aagcacgc	gaaaggactt	1860
gaatcagctc	aactggattt	aaatggcaaa	aggcatgag	agaacaa	gcaaggggat	1920
gctggagatc	cacccctgt	gagcaaattt	tgcgtgc	ccaatgg	tttgcgtat	1980
tgtgcttc	ttgctgt	tgttacata	ggctgt	tatgtaa	atcacgtgt	2040
aaactgtcg	caccgcgt	agctaatat	tatcatgtat	gtgggcact	aatgccacc	2100
ttggccatac	ccaaccgtcc	taaaacgattt	tcacgtcg	gtaactta	tgagataca	2160
ctttcagtat	attcagcaaa	aggaattt				2188

## Mouse PrP cDNA (SEQ ID NO:7; GenBank Accession No. M13685)

aattccctca	gaactgaacc	atttcaacc	agctgaagca	ttctgccttc	ctagtgg	60
cagtccaa	taggagagcc	aagcagacta	tcagtcata	tggcaac	tggctactgg	120
ctgctggccc	tctttgt	tatgtggact	gatgtcg	tctgc	aaaaaa	180
cctggagggt	ggaacacc	ttggaa	ccgg	tatccc	ggggccc	240
cgttacccac	ctcagg	gggg	caccc	gggg	ttgg	300
catggggca	gctggg	gaca	ccat	gggg	gggg	360
tggggcaag	gggggg	tac	ccata	gggg	gggg	420
ctcaagcat	tggcagg	gggg	tcgcgc	gggg	gggg	480
atgtggg	gcccgt	gggg	ccat	gggg	gggg	540
tactaccgt	aaaacat	ggctacc	acc	gggg	gggg	600
tacagcaacc	agaaca	actt	ctgcac	gggg	gggg	660
gtcaccacca	ccacca	gggg	actt	gggg	gggg	720
gtgggg	agatgt	gggg	ccac	gggg	gggg	780
agaagatcca	gcagcacc	gtttt	tcac	gggg	gggg	840
ctcatcttcc	tgatcg	tttt	tcgt	gggg	gggg	900
gtctagg	gggg	tttt	ctgt	gggg	gggg	960

- 11 -

ttgcttcct	gtgtccccca	taggctaata	cccccggcac	tgatggggcc	tggggaaatgt	1020
acagtagacc	agtgtcttt	tgcttcagg	ccctttagt	gagtctgtca	tcagccagtg	1080
ctaaccacgg	gccaataaga	atataaaccc	aaataactgc	tggctagttg	gggctttgtt	1140
ttggtctagt	gaataaaatc	tgggtatcc	cctgacttgt	acccagagta	caaggtgaca	1200
gtgacacatg	taacttagca	taggcaaagg	gttctacaac	caaagaagcc	actgtttggg	1260
gatggcgccc	tggaaaacag	cctccccacct	gggatagcta	gagcatccac	acgtggaatt	1320
ctttcttac	taacaaacga	tagctgattt	aaggcaacaa	aaaaaaaaaa	atcaaattgt	1380
cctactgacg	ttgaaaagcaa	acctttgttc	attcccagg	cactagaatg	atcttagcc	1440
ttgcttgat	tgaacttagga	gatcttgact	ctgaggagag	ccagccctgt	aaaaagcttg	1500
gtccctctgt	gacggggaggg	atggtaagg	tacaaaggct	agaaaacttga	gtttcttcat	1560
ttctgtctca	caatttatcaa	aagctagaat	tagttctgc	cctatgtttc	tgtacttcta	1620
tttgaacttgg	ataaacagaga	gacaatctaa	acattctt	aggctgcaga	taagagaagt	1680
aggctccatt	ccaaagtggg	aaagaaaattc	tgctagcatt	gtttaaatca	ggcaaaattt	1740
gttcctgaag	ttgtttttt	ccccagcaga	cataaaactgc	gatagttca	gcttgcactg	1800
tggattttct	gtatagaata	tataaaaacat	aacttcaagc	ttatgtcttc	ttttaaaac	1860
atctgaagta	tgggacgccc	tggccgttcc	atccagttact	aaatgcttac	cgtgtgaccc	1920
ttgggcttc	agcgtgcact	cagttccgt	ggattccaaa	gcagaccct	agctggtctt	1980
tgaatctgca	tgtacttca	gtttctata	tttgcata	tgcatgtatt	ttgtttgtc	2040
atataaaaag	tttataaaatg	tttgctatca	gactgacatt	aaatagaagc	tatgtatg	2097

Sheep PrP cDNA (SEQ ID NO:8; GenBank Accession No. X79912)

gcagagaagt	catcatggtg	aaaagccaca	taggcagttg	gatcctgggt	ctctttgtgg	60
ccatgtggag	tgacgtgggc	ctctgcaaga	agcgacccaa	acctggcgga	ggatggaaca	120
ctggggggag	ccgataccgg	ggacagggca	gtcctggagg	caaccgctat	ccacactcagg	180
gaggggggtgg	ctggggtgcag	ccccatggag	gtggctgggg	ccaacctat	ggaggtggct	240
ggggtcagcc	ccatgggtgt	ggctgggac	agccacatgg	tggtgagggc	tgggtcaag	300
gtggtagcca	cagtcagtgg	aacaagccca	gtaagccaaa	aaccaacatg	aagcatgtgg	360
caggagctgc	tgcagctgg	gcagttgttag	ggggccttgg	tggctacatg	ctgggaagtgg	420
ccatgagcag	gcctttata	cattttggca	atgactatga	ggaccgttac	tatcgtgaaa	480
acatgtaccg	ttaccccaac	caagtgtact	acagaccagt	ggatcagttat	agtaaccaga	540
acaactttgt	gcatgactgt	gtcaacatca	cagtcagca	acacacagtc	accaccacca	600
ccaaggggga	gaacttcacc	gaaaactgaca	tcaagataat	ggagcgagtg	gtggagcaaa	660
tgtgcattcac	ccagtaccag	agagaatccc	aggcttatta	ccaaaggggg	gcaagtgtga	720
tcctcttttc	ttccccctct	gtgatccctcc	tcatctctt	cctcattttt	ctcatagtag	780
gataggggca	acccctctgt	ttt				803

Rat PrP cDNA (SEQ ID NO:9; GenBank Accession No. NM\_012631)

atggcgaacc	ttggctactg	gctgctggcc	ctcttgtga	ctatcatgtac	tgatgtggc	60
ctctgcaaaa	agccggccaaa	gcctgggggg	tggaacactg	gtggaagccg	gtaccctggg	120
cagggaaagcc	ctggaggcaaa	ccgttaccca	cctcagagtg	gtggtagctg	ggggcagcccc	180
catggtggtg	gctggggaca	acctcatgtt	ggtgctggg	gacaacctca	tgggtgtggc	240
tggggtcagc	cccatggcg	gggctggagt	caaggagggg	gtaccctaaa	tcagtggaac	300
aagcccagca	agccaaaaac	caacctcaag	catgtggcag	gggctgcccgc	agctggggca	360
gtagtggggg	gccttggtgg	ctacatgtt	gggagtgcca	tgagcaggcc	catgtccat	420
tttggcaacg	actggggagga	ccgtctactac	cgagaaaaaca	tgtaccgtt	ccctaaccac	480
gtgtactaca	ggccgggtga	tcagtgacagc	aaccagaaca	acttcgtgca	cgactgtgtc	540
aatatcacca	tcaagcagca	tacagtccacc	accaccacca	agggggagaa	cttcacggag	600
accgacgtga	agatgtatgg	gcgtgtggtg	gagcagatgt	gcgtcaccca	gtatcagaag	660
gagttcccaagg	cctattacga	cgggagaaga	tctagcggcc	tgctttctc	ctccccctcct	720
gtgatccctcc	tcatctcctt	cctcatcttc	ctgatcgtgg	gatga		765

As used herein, "prion disease" refers to any disease or condition in a subject, the pathogenesis of which involves a prion protein other than PrP<sup>C</sup> of the species of the subject.

- 12 -

A prion disease will typically but not necessarily be a transmissible spongiform encephalopathy.

As used herein, “transmissible spongiform encephalopathy” and, equivalently, “(TSE)” shall mean any prion disease that is associated with spongiform encephalopathy and is communicable from one individual to another. As prion diseases can include entities other than TSE, this term refers to at least a subset of all prion diseases. At present TSE includes Creutzfeldt-Jakob disease, kuru, Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia, bovine spongiform encephalopathy, and scrapie.

As used herein, “Creutzfeldt-Jakob disease” and, equivalently, “(CJD)” refers to the TSE that naturally occurs in humans. CJD includes sporadic, genetic (familial), and infectious (i.e., variant and iatrogenic) forms. CJD is a well described entity in the medical literature, and until now has been widely believed to be a uniformly fatal neurodegenerative disease for which there is no effective form of treatment.

As used herein, “variant Creutzfeldt-Jakob disease” and, equivalently, “(vCJD)”, also referred to in the literature as new variant Creutzfeldt-Jakob disease (nvCJD), refers to CJD attributable to the BSE prion. It can be distinguished from sporadic CJD not only by the prion involved but also by certain clinical and preclinical features. See Aguzzi A (2000) *Haematologica* 85:3-10; Hill AF et al. (1997) *Nature* 389:448-50; Bruce ME et al. (1997) *Nature* 389:498-501; Will R et al. (1996) *Lancet* 347:921-5.

As used herein, “iatrogenic Creutzfeldt-Jakob disease” and, equivalently, “(iCJD)” refers to any form of CJD that is attributable to work- or treatment-related exposure to prion protein that is associated with CJD.

As used herein, “bovine spongiform encephalopathy” and, equivalently, “(BSE)” shall refer to the TSE that occurs naturally in cows and cattle.

As used herein, “scrapie” refers to the TSE that occurs naturally in sheep and goats, as well as to experimental models of scrapie. Scrapie in sheep has been recognized and described in the literature for over 300 years. For a review, see O’Rourke KI (2001) *Vet Clin North Am Food Anim Pract* 17:283-300.

As used herein, a “prion protein that is associated with a prion disease” refers to any prion protein involved in the pathogenesis of a prion disease. A prion protein that is associated with a prion disease can be a prion found in nature. Alternatively, prion protein that is associated with a prion disease can be a prion protein made de novo or modified from

- 13 -

its natural form through human activity, e.g., by in vitro synthesis, chemical synthesis, chemical derivatization, or genetic alteration. Chemical alteration includes, without limitation, altered glycosylation. In a preferred embodiment, a prion protein that is associated with a prion disease is a prion protein found in nature, e.g., PrP<sup>Sc</sup>. In one embodiment, a prion protein that is associated with a prion disease is a truncated or genetically modified form of a prion protein found in nature. A genetically modified form of a prion protein found in nature includes a fusion protein involving at least a substantial portion of a prion protein as one component, a prion protein that differs from a prion protein found in nature by one or more conservative amino acid substitutions, and allelic variants of the prion protein found in nature.

Naturally occurring residues can be divided into the following classes based on common side chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr; (3) acidic: Asp, Glu; (4) basic: Asn, Gln, His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe. Thus, for example, conservative amino acid substitutions can involve the exchange of a member from one of these classes for another member from the same class. Non-conservative amino acid substitutions can involve the exchange of a member of one of these classes for a member from another class.

A conservative amino acid substitution can involve a substitution of a native amino acid residue with another residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues that are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics, and other reversed or inverted forms of amino acid moieties.

As used herein, "prion protein:scrapie form (PrP<sup>Sc</sup>)" refers to any of a number of naturally occurring, species-specific, proteinase K-resistant forms of prion protein associated with prion disease. Specific examples include, but are not limited to, the following: human PrP<sup>Sc</sup> having an amino acid sequence provided by SEQ ID NO:10; bovine PrP<sup>Sc</sup> having an amino acid sequence provided by SEQ ID NO:11; bovine PrP<sup>Sc</sup> having an amino acid sequence provided by SEQ ID NO:12; ovine PrP<sup>Sc</sup> having an amino acid sequence provided by SEQ ID NO:13; ovine PrP<sup>Sc</sup> having an amino acid sequence provided by SEQ ID NO:14; and murine PrP<sup>Sc</sup> having an amino acid sequence provided by SEQ ID NO:15.

- 14 -

**Human PrP<sup>Sc</sup> (SEQ ID NO:10; GenBank Accession No. AAE81600)**

MANLGWCMLV	LFVATWSDLG	LCKKRKP <span style="font-variant: small-caps;">pg</span>	WNTGGSRYPG	QGSPGGNRYP	PQGGGGWGQP	60
HGGGWGQPHG	GGWGQPHGGG	WGQPHGGGWG	QGGGTHSQWN	KPSKP <span style="font-variant: small-caps;">tn</span> MK	HMA <span style="font-variant: small-caps;">aa</span> AGA	120
VVGGLGGYML	GSAMSRPIIH	FGSDYEDRYY	RENMRYPNQ	VYYRP <span style="font-variant: small-caps;">de</span> YS	NQNNFVHDCV	180
NITIKQHTVT	TTTKGENFTE	TDVKMMERVV	EQMCITQYER	ESQAYYQRGS	SMVLFSSPPV	240
ILLISFLIFL	IVG					253

**Bovine PrP<sup>Sc</sup> (SEQ ID NO:11; GenBank Accession No. AAE81601)**

MVKSHIGSWI	LVLFVAMWSD	VGLCKKRKP <span style="font-variant: small-caps;">p</span>	GGWNTGGSR	PGQGSPGGNR	YPPQGGGGWG	60
QPHGGGWGQP	HGGGWGQPHG	GGWGQPHGGG	WGQPHGGGWG	QGGGTHGQWN	KPSKP <span style="font-variant: small-caps;">tn</span> MK	120
HVAGAAAAGA	VVGGLGGYML	GSAMSRPLIH	FGSDYEDRYY	RENMRYPNQ	VYYRP <span style="font-variant: small-caps;">d</span> QYS	180
NQNNFVHDCV	NITVKEHTVT	TTTKGENFTE	TDIKMMERVV	EQMCVTQYQK	ESQAYYDQGA	240
SVILFSSPPV	ILLISFLIFL	IVG				263

**Bovine PrP<sup>Sc</sup> (SEQ ID NO:12; GenBank Accession No. CAA39368)**

MVKSHIGSWI	LVLFVAMWSD	VGLCKKRKP <span style="font-variant: small-caps;">p</span>	GGWNTGGSR	YPGQGSPGGN	YPPQGGGGWG	60
GQPHGGGWGQ	PHGGGWGQPH	GGWGQPHGG	WGQPHGGGG	WGQGGTHGQW	NKPSKP <span style="font-variant: small-caps;">tn</span> M	120
KHVAGAAAAG	AVVGGLGGY	LGSAMSRPLI	HFGSDYEDRY	YRENMRYPN	QVYYRP <span style="font-variant: small-caps;">d</span> QY	180
SNQNNFVHDC	VNITVKEHTV	TTTTKGENFT	ETDIKMMERVV	VEQMCITQYQ	RESQAYYQRG	240
ASVILFSSPP	VILLISFLIF	LIVG				264

**Ovine PrP<sup>Sc</sup> (SEQ ID NO:13; GenBank Accession No. AAE81602)**

MVKSHIGSWI	LVLFVAMWSD	VGLCKKRKP <span style="font-variant: small-caps;">p</span>	GGWNTGGSR	PGQGSPGGNR	YPPQGGGGWG	60
QPHGGGWGQP	HGGGWGQPHG	GSWGQPHGGG	GWGQGGSHSQ	WNKPSKP <span style="font-variant: small-caps;">tn</span> T	MKHVAGAAA	120
GAVVGGLGGY	MLGSAMSRPL	IHF <span style="font-variant: small-caps;">nd</span> YEDR	YYRENMYRYP	NQVYYRP <span style="font-variant: small-caps;">d</span> Q	YSNQNNFVHD	180
CVNITVKQHT	VTTTKGENF	TETDIKIMER	VVEQMCITQY	QRESQAYYQR	GASVILFSSP	240
PVILLISFLI	FLIVG					255

**Ovine PrP<sup>Sc</sup> (SEQ ID NO:14; GenBank Accession No. CAA56283)**

MVKSHIGSWI	LVLFVAMWSD	VGLCKKRKP <span style="font-variant: small-caps;">p</span>	GGWNTGGSR	YPGQGSPGGN	YPPQGGGGWG	60
GQPHGGGWGQ	PHGGGWGQPH	GGWGQPHGG	WGQGGSHS	QWNKPSKP <span style="font-variant: small-caps;">kt</span>	NMKHVAGAAA	120
AGAVVGLGG	YMLGSAMSRP	LIHF <span style="font-variant: small-caps;">nd</span> YED	YYRENMYRYP	PNQVYYRP <span style="font-variant: small-caps;">d</span> Q	YSNQNNFVH	180
DCVNITVKQH	TVTTTKGEN	FTETDIKIME	RVVEQMCITQ	YQRESQAYYQ	RGASVILFSS	240
PPVILLISFL	IFLIVG					256

**Murine PrP<sup>Sc</sup> (SEQ ID NO:15; GenBank Accession No. AAE81599)**

- 15 -

MANLGYWLLA	LFVTMWTDVG	LCKKRPKPGG	WNTGGSRYPG	QGSPGGNRYP	PQGGTWGQPH	60
GGGWGQPHGG	SWGQPHGGSW	GQPHGGGWGQ	GGGTHNQWNK	PSKPKNLKH	VAGAAAAGAV	120
VGGLGGYMLG	SAMSRPMIHF	GNDWEDRYYR	ENMYRYPNQV	YYRPVDQYSN	QNNFVHDCVN	180
ITIKQHTVTT	TTKGENFTET	DVKMMERVVE	QMCVTQYQKE	SQAYYDGRRS	SSTVLFSSPP	240
VILLISFLIF	LIVG					254

As used herein, "full-length PrP<sup>Sc</sup>" refers to a form of PrP<sup>Sc</sup> that includes all its amino acids as it occurs in nature. It is to be distinguished, for example, from a truncated form of PrP<sup>Sc</sup>, described elsewhere herein. A full-length PrP<sup>Sc</sup> can, however, be incorporated into a PrP<sup>Sc</sup> conjugate or PrP<sup>Sc</sup> fusion protein.

As used herein, a "derivative of PrP<sup>Sc</sup>" refers to a chemical or genetic derivative of a naturally occurring form of PrP<sup>Sc</sup>, including PrP<sup>Sc</sup> with non-native glycosylation, covalent or non-covalent conjugates formed between PrP<sup>Sc</sup> and another compound, PrP<sup>Sc</sup> fusion proteins, and any combination thereof. A "derivative of a fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup>," refers to a chemical or genetic derivative of an N-terminally truncated form of PrP<sup>Sc</sup>, including such truncated forms of PrP<sup>Sc</sup>: (i) with non-native glycosylation, (ii) as part of a covalent or non-covalent conjugate formed with another compound, (iii) as part of a fusion protein, or (iv) any combination thereof. In preferred embodiments the fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup> refers to a fragment lacking one or more, up to and including all, of the octarepeats (e.g., GGGWGQPH (SEQ ID NO:16) and GGSWGQPH (SEQ ID NO:17)). See Flechsig E et al. (2000) *Neuron* 27:399-408.

A truncated form of a prion protein found in nature is identical in primary sequence to the prion protein found in nature except for the absence of one or more amino acid residues from the N-terminal end, the C-terminal end, or both the N-terminal and the C-terminal ends. Truncated forms can also include deletion mutants, in which an internal sequence is omitted without changing either the N-terminal end or the C-terminal end. In a preferred embodiment, a truncated prion protein lacks one or more, up to and including all, N-terminal octarepeats (e.g., GGGWGQPH and GGSWGQPH). See Flechsig E et al. (2000) *Neuron* 27:399-408.

As used herein, a "fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup>," shall refer to a truncated form of full-length PrP<sup>Sc</sup> lacking one or more N-terminal amino acids normally present in full-length PrP<sup>Sc</sup>. In a preferred embodiment, the fragment

- 16 -

lacks one or more, up to and including all, of the octarepeats (e.g., GGGWGQPH and GGSWGQPH). See Flechsig E et al. (2000) *Neuron* 27:399-408.

The methods of the instant invention employ immunostimulatory nucleic acids. In the preferred embodiment, the immunostimulatory nucleic acid is a CpG nucleic acid. The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymidine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid backbone with nucleic acid bases).

Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymidine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties. Other such modifications are well known to those of skill in the art.

The immunostimulatory oligonucleotides of the instant invention can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a  $\beta$ -D-ribose unit and/or a natural

- 17 -

nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" Synthesis and Properties & Synthesis and Analytical Techniques, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth Methods* 7:331-417. An oligonucleotide according to the invention can have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular  $\beta$ -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is composed of natural DNA or RNA.

For example, the invention relates to an oligonucleotide which comprises one or more modifications and wherein each modification is independently selected from:

- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
- b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge,
- c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
- d) the replacement of a  $\beta$ -D-ribose unit by a modified sugar unit, and
- e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate,  $\text{NR}^1\text{R}^2$ -phosphoramidate, boranophosphate,  $\alpha$ -hydroxybenzyl phosphonate, phosphate-( $\text{C}_1$ - $\text{C}_{21}$ )-O-alkyl ester, phosphate-[( $\text{C}_6$ - $\text{C}_{12}$ )aryl-( $\text{C}_1$ - $\text{C}_{21}$ )-O-alkyl]ester, ( $\text{C}_1$ - $\text{C}_8$ )alkyl-phosphonate and/or ( $\text{C}_6$ - $\text{C}_{12}$ )-arylphosphonate bridges, ( $\text{C}_7$ - $\text{C}_{12}$ )- $\alpha$ -hydroxymethyl-aryl (e.g., disclosed in WO 95/01363), wherein ( $\text{C}_6$ - $\text{C}_{12}$ )aryl, ( $\text{C}_6$ - $\text{C}_{20}$ )aryl and ( $\text{C}_6$ - $\text{C}_{14}$ )aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where  $\text{R}^1$  and  $\text{R}^2$  are, independently of each other, hydrogen, ( $\text{C}_1$ - $\text{C}_{18}$ )-alkyl, ( $\text{C}_6$ - $\text{C}_{20}$ )-aryl, ( $\text{C}_6$ - $\text{C}_{14}$ )-aryl-( $\text{C}_1$ - $\text{C}_8$ )-alkyl, preferably hydrogen, ( $\text{C}_1$ - $\text{C}_8$ )-alkyl, preferably ( $\text{C}_1$ - $\text{C}_4$ )-alkyl and/or methoxyethyl, or  $\text{R}^1$  and  $\text{R}^2$  form, together with

- 18 -

the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa 1993, Chapter 16, pp. 355ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazo, dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a  $\beta$ -D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer (as described, for example, in Stinchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine.

A  $\beta$ -ribose unit or a  $\beta$ -D-2'-deoxyribose unit can be replaced by a modified sugar unit, wherein the modified sugar unit is for example selected from  $\beta$ -D-ribose,  $\alpha$ -D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose, preferably 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose is 2'-O-methylribose, 2'-O-(C<sub>2</sub>-C<sub>6</sub>)alkenyl-ribose, 2'-[O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl]-ribose, 2'-NH<sub>2</sub>-2'-deoxyribose,  $\beta$ -D-xylo-furanose,  $\alpha$ -arabinofuranose, 2,4-dideoxy- $\beta$ -D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).

A natural nucleoside base can be replaced by a modified nucleoside base, wherein the modified nucleoside base is for example selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil, 4-thiouracil, 5-aminouracil, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine,

- 19 -

5-bromocytosine, N<sup>2</sup>-dimethylguanosine, 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably 7-deaza-7-substituted and/or 7-deaza-8-substituted purine or other modifications of a natural nucleoside bases. This list is meant to be exemplary and is not to be interpreted to be limiting.

The oligonucleotides of the present invention are nucleic acids that contain specific sequences found to elicit an immune response. These specific sequences that elicit an immune response are referred to as "immunostimulatory motifs", and the oligonucleotides that contain immunostimulatory motifs are referred to as "immunostimulatory nucleic acid molecules" and, equivalently, "immunostimulatory nucleic acids" or "immunostimulatory oligonucleotides". The immunostimulatory oligonucleotides of the invention thus include at least one immunostimulatory motif.

In one embodiment of the invention the immunostimulatory oligonucleotides include immunostimulatory motifs which are "CpG dinucleotides". A CpG dinucleotide can be methylated or unmethylated. An immunostimulatory nucleic acid containing at least one unmethylated CpG dinucleotide is a nucleic acid molecule which contains an unmethylated cytosine-guanine dinucleotide sequence (i.e., an unmethylated 5' cytosine followed by 3' guanosine and linked by a phosphate bond) and which activates the immune system; such an immunostimulatory nucleic acid is a CpG nucleic acid. CpG nucleic acids have been described in a number of issued patents, published patent applications, and other publications, including U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068.

An immunostimulatory nucleic acid containing at least one methylated CpG dinucleotide is a nucleic acid which contains a methylated cytosine-guanine dinucleotide sequence (i.e., a methylated 5' cytosine followed by a 3' guanosine and linked by a phosphate bond) and which activates the immune system. In other embodiments the immunostimulatory oligonucleotides are free of CpG dinucleotides. These oligonucleotides which are free of CpG dinucleotides are referred to as non-CpG oligonucleotides, and they have non-CpG immunostimulatory motifs. The invention, therefore, also encompasses nucleic acids with other types of immunostimulatory motifs, which can be methylated or unmethylated. The immunostimulatory oligonucleotides of the invention, further, can include any combination of methylated and unmethylated CpG and non-CpG

- 20 -

immunostimulatory motifs. In some embodiments the immunostimulatory oligonucleotide is not an antisense oligonucleotide.

As used herein, a "Toll-like receptor (TLR) that signals in response to the CpG nucleic acid" refers to any TLR that engages or initiates an intracellular signaling pathway associated with the development of an immune response, as a result of contacting the TLR with CpG nucleic acid. The pathway typically involves the adaptor protein MyD88 and subsequent downstream molecules including TRAF, IRAK, Jun, Erk, p38 MAPK, and NF- $\kappa$ B. The TLRs are a family of at least ten highly conserved receptors that share as a common feature a cytoplasmic Toll homology IL-1 receptor (TIR) domain believed to be involved in such signaling. TLR9 is reported to be the natural receptor for CpG nucleic acid.

As to CpG nucleic acids, it has recently been described that there are different classes of CpG nucleic acids. One class is potent for activating B cells but is relatively weak in inducing IFN- $\alpha$  and NK cell activation; this class has been termed the B class. The B class CpG nucleic acids typically are fully stabilized and include an unmethylated CpG dinucleotide within certain preferred base contexts. See, e.g., U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Another class is potent for inducing IFN- $\alpha$  and NK cell activation but is relatively weak at stimulating B cells; this class has been termed the A class. The A class CpG nucleic acids typically have stabilized poly-G sequences at 5' and 3' ends and a palindromic phosphodiester CpG dinucleotide-containing sequence of at least 6 nucleotides. See, for example, published patent application PCT/US00/26527 (WO 01/22990). Yet another class of CpG nucleic acids activates B cells and NK cells and induces IFN- $\alpha$ ; this class has been termed the C class. The C class CpG nucleic acids typically are fully stabilized, include a B class-type sequence and a GC-rich palindrome or near-palindrome. This class has been described in published patent application PCT/US02/26468 (WO 03/015711), the entire content of which is incorporated herein by reference.

Immunostimulatory oligonucleotides are effective in vertebrates. Different immunostimulatory oligonucleotides can cause optimal immune stimulation depending on the type of subject and the sequence of the immunostimulatory oligonucleotide. Many vertebrates have been found according to the invention to be responsive to the same class of immunostimulatory oligonucleotides, sometimes referred to as human specific immunostimulatory oligonucleotides. Rodents, however, respond to different nucleic acids.

Immunostimulatory oligonucleotides causing optimal stimulation in humans may not generally cause optimal stimulation in a mouse and vice versa. An immunostimulatory oligonucleotide causing optimal stimulation in humans often does, however, cause optimal stimulation in other animals such as cow, horses, sheep, etc. For example, within Class B CpG ODN, preferred immunostimulatory sequences have been identified for use in mice (ODN 1826, 5'- TCCATGACGTTCTGACGTT -3', SEQ ID NO:18) and for use in humans (ODN 2006, 5'- TCGTCGTTTGTCTGTTTGTCTGTT -3', SEQ ID NO:19). One of skill in the art can identify the optimal immunostimulatory nucleic acid sequences useful for a particular species of interest using routine assays described herein and/or known in the art, using the guidance supplied herein.

As used herein, the term "treat" as used in reference to a disease or condition shall mean to intervene in such disease or condition so as to prevent or slow the development of, slow the progression of, halt the progression of, or eliminate the disease or condition. Thus the phrase "to treat the prion disease" as used herein means to prevent or slow the development of, slow the progression of, halt the progression of, or eliminate the prion disease.

As used herein, a "subject" refers to a human or non-human vertebrate. Preferred non-human vertebrates include feed livestock susceptible to TSE, including cows and cattle, sheep, goats, and pigs. Non-human subjects also specifically include non-human primates as well as rodents. Non-human subjects also include, without limitation, chickens, horses, dogs, cats, guinea pigs, hamsters, mink, and rabbits.

As used herein, a "subject having a prion disease" is a subject known or diagnosed to have a prion disease as disclosed herein. Generally a subject having a prion disease will have some objective manifestation of the prion disease, such as a sign, symptom, or result of a suitable diagnostic test that indicates the presence of a prion disease. In the transmissible spongiform encephalopathies, such objective manifestations can include dementia, ataxia, myoclonus, tremor, presence of protease-resistant prion protein in brain extract, and typical or characteristic abnormalities on brain CT, brain MRI, and/or EEG. This list is not meant to be limiting in any way, and those of skill in the art will recognize what criteria are suitable for making a diagnosis of prion disease in a given species in question. A subject having a prion disease shall also include any subject having a test result which specifically indicates the presence in that subject of any amount of prion protein that is associated with a prion

- 22 -

disease, since it is believed that prion protein that is associated with a prion disease is not present in a subject without a prion disease.

A subject having a prion disease can but need not necessarily have an identifiable risk factor for having a prion disease. An identifiable risk factor for having a prion disease can include a family history of prion disease, a history of consuming known or suspected prion-diseased tissue, or a history of exposure to a prion protein that is associated with a prion disease or to a product derived from a known or suspected prion-diseased tissue (e.g., through administration of pituitary extract).

As used herein, a "subject at risk of developing a prion disease" is a subject with a known or suspected exposure to prion-diseased tissue, a known or suspected exposure to prion protein that is associated with a prion disease, or a known or suspected predisposition to develop a prion disease (e.g., family history of prion disease). In one embodiment the subject at risk of developing a prion disease is a subject residing in or traveling to an area in which TSE is endemic. In one embodiment the subject at risk of developing a prion disease is a subject residing in or traveling to an area in which food or water contains or is likely to contain prion protein that is associated with prion disease. In one embodiment, a subject at risk of developing a prion disease is a subject with a known or suspected iatrogenic exposure to prion-diseased tissue, e.g., neurosurgeons, neuropathologists, pathologists, nurses, morticians, histology technicians and laboratory workers at special risk of contracting iCJD. In one embodiment, a subject at risk of developing a prion disease is a subject with a known or suspected iatrogenic exposure to prion-diseased tissue through receiving a tissue or organ allograft from a subject having a prion disease. Such tissues can include, without limitation, corneas and dural grafts.

As used herein, an "effective amount" of a substance generally refers to that amount of the substance that is sufficient to bring about a desired effect. With reference to CpG nucleic acid, an "effective amount to induce an immune response to the prion protein" shall refer to that amount of CpG nucleic acid that is sufficient to induce an immune response to a particular prion protein. The immune response can occur *in vitro*, *in vivo*, *ex vivo*, and any combination thereof. An immune response to a prion protein can be measured using any suitable means to determine that an immune response occurs in association with exposure of an immune cell to the prion protein. The immune response can be antigen-specific, including any of the following: production of prion protein-specific antibody, proliferation of prion

- 23 -

protein-specific lymphocytes, and cell-mediated immunity against cells expressing prion protein. The immune response can alternatively or additionally be antigen-nonspecific, including any of the following: induction of a Toll-like receptor signaling pathway, inflammation, and production of a cytokine and/or chemokine. Because prion proteins are generally believed not to evoke an immune response, any prion protein-specific immune response which occurs in association with exposure of an immune cell to a prion protein will generally indicate an immune response to the prion protein.

Also with reference to CpG nucleic acid, an "effective amount to treat the prion disease" shall refer to that amount of CpG nucleic acid that is sufficient to treat a particular prion disease. In one embodiment, an effective amount to treat the prion disease is that amount that is sufficient to slow the development of prion disease, compared to the rate of development of prion disease that would occur without CpG administration according to the instant invention. In one embodiment, an effective amount to treat the prion disease is that amount that is sufficient to prevent the development of prion disease, compared to development of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to slow the progression of prion disease, compared to the rate of progression of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to stop the progression of prion disease, compared to the progression of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to resolve prion disease, compared to the prion disease that would occur without CpG administration according to the instant invention.

Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular immunostimulatory oligonucleotide being administered, the antigen, the size of the subject, or the severity of the disease or condition.

- 24 -

One of ordinary skill in the art can empirically determine the effective amount of a particular immunostimulatory oligonucleotide and/or other therapeutic agent without necessitating undue experimentation.

Subject doses of the immunostimulatory oligonucleotides for mucosal or local delivery typically range from about 0.1  $\mu$ g to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically doses range from about 10  $\mu$ g to 5 mg per administration, and most typically from about 100  $\mu$ g to 1 mg, with repeated administrations being spaced days or weeks apart. Subject doses of immunostimulatory oligonucleotides for parenteral delivery for the purpose of inducing an antigen-specific immune response, wherein the compounds are delivered with an antigen but not another therapeutic agent are typically 5 to 10,000 times higher than the effective mucosal dose for vaccine adjuvant or immune stimulant applications, and more typically 10 to 1,000 times higher, and most typically 20 to 100 times higher. Doses of the immunostimulatory oligonucleotides for parenteral delivery for the purpose of inducing an innate immune response or for inducing an antigen-specific immune response when the immunostimulatory nucleic acids are administered in combination with other therapeutic agents or in specialized delivery vehicles typically range from about 0.1  $\mu$ g to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically parenteral doses for these purposes range from about 10  $\mu$ g to 5 mg per administration, and most typically from about 100  $\mu$ g to 1 mg, with repeated administrations being spaced days or weeks apart. In some embodiments, however, parenteral doses for these purposes may be used in a range of 5 to 10,000 times higher than the typical doses described above.

For any immunostimulatory oligonucleotide the therapeutically effective amount can be initially determined from animal models. A therapeutically effective dose can also be determined from human data for CpG oligonucleotides which have been tested in humans (human clinical trials have been initiated) and for compounds which are known to exhibit similar pharmacological activities, such as other mucosal adjuvants, e.g., LT and other antigens for vaccination purposes, for mucosal or local administration. Higher doses are required for parenteral administration. The applied dose can be adjusted based on the relative bioavailability and potency of the administered immunostimulatory oligonucleotide. Adjusting the dose to achieve maximal efficacy based on the methods described herein and

- 25 -

other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.

The immunostimulatory oligonucleotide can be administered alone or with antigen or other therapeutic agent. In this context, "antigen" refers to any biological molecule capable of eliciting specific immunity. Antigens specifically include peptides (oligopeptides, polypeptides, proteins, and glycosylated derivatives thereof), and polysaccharides. Peptide antigen can be administered preformed or as a polynucleotide encoding the peptide. Also in this context, "other therapeutic agent" includes any suitable composition useful in treating prion disease, including an antibody capable of binding a prion protein. When the immunostimulatory oligonucleotide is administered with antigen or other therapeutic agent, the immunostimulatory oligonucleotide can be administered before, concurrently with, or following administration of the antigen or other therapeutic agent. The immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be formulated together or separately when the immunostimulatory oligonucleotide is administered concurrently with the antigen or other therapeutic agent. When the immunostimulatory oligonucleotide is administered before or following administration of antigen or other therapeutic agent, the immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be administered by the same route of administration or by different routes of administration. In addition, when the immunostimulatory oligonucleotide is administered before or following administration of antigen or other therapeutic agent, the immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be administered to the same site or to different sites.

The immunostimulatory oligonucleotides may be directly administered to the subject or may be administered in conjunction with a nucleic acid delivery complex. A nucleic acid delivery complex shall mean a nucleic acid molecule associated with (e.g., ionically or covalently bound to; or encapsulated within) a targeting means (e.g., a molecule that results in higher affinity binding to target cell (e.g., B cell surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with a sterol (e.g., cholesterol), a lipid (e.g., a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g., a ligand recognized by target cell specific receptor). Preferred complexes may be sufficiently stable *in vivo* to prevent significant uncoupling prior to internalization by the target cell. However, the complex can

- 26 -

be cleavable under appropriate conditions within the cell so that the nucleic acid is released in a functional form.

Delivery vehicles or delivery devices for delivering antigen and nucleic acids to surfaces have been described. The immunostimulatory oligonucleotide and/or the antigen and/or other therapeutics may be administered alone (e.g., in saline or buffer) or using any delivery vehicles known in the art. For instance the following delivery vehicles have been described: cochleates (Gould-Fogerite et al., 1994, 1996); emulsomes (Vancott et al., 1998, Lowell et al., 1997); ISCOMs (Mowat et al., 1993, Carlsson et al., 1991, Hu et., 1998, Morein et al., 1999); liposomes (Childers et al., 1999, Michalek et al., 1989, 1992, de Haan 1995a, 1995b); live bacterial vectors (e.g., *Salmonella*, *Escherichia coli*, bacillus Calmette-Guérin, *Shigella*, *Lactobacillus*) (Hone et al., 1996, Pouwels et al., 1998, Chatfield et al., 1993, Stover et al., 1991, Nugent et al., 1998); live viral vectors (e.g., Vaccinia, adenovirus, Herpes Simplex) (Gallichan et al., 1993, 1995, Moss et al., 1996, Nugent et al., 1998, Flexner et al., 1988, Morrow et al., 1999); microspheres (Gupta et al., 1998, Jones et al., 1996, Maloy et al., 1994, Moore et al., 1995, O'Hagan et al., 1994, Eldridge et al., 1989); nucleic acid vaccines (Fynan et al., 1993, Kuklin et al., 1997, Sasaki et al., 1998, Okada et al., 1997, Ishii et al., 1997); polymers (e.g., carboxymethylcellulose, chitosan) (Hamajima et al., 1998, Jabbal-Gill et al., 1998); polymer rings (Wyatt et al., 1998); proteosomes (Vancott et al., 1998, Lowell et al., 1988, 1996, 1997); sodium fluoride (Hashi et al., 1998); transgenic plants (Tacket et al., 1998, Mason et al., 1998, Haq et al., 1995); virosomes (Gluck et al., 1992, Mengiardi et al., 1995, Cryz et al., 1998); virus-like particles (Jiang et al., 1999, Leibl et al., 1998).

The immunostimulatory oligonucleotides may be administered by any means known to the skilled artisan. Routes of administration include but are not limited to oral, mucosal, parenteral, intravenous, intramuscular, intraperitoneal, intranasal, intratracheal, sublingual, subcutaneous, intradermal, inhalation, ocular, vaginal, and rectal.

The immunostimulatory oligonucleotides are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic

- 27 -

gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer R (1990) *Science* 249:1527-33, which is incorporated herein by reference.

The immunostimulatory oligonucleotides and optionally other therapeutics and/or antigens may be administered *per se* (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

For oral administration, the immunostimulatory oligonucleotides can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose,

- 28 -

mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The immunostimulatory oligonucleotides, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The immunostimulatory oligonucleotides may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the immunostimulatory oligonucleotides may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

The term "pharmaceutically-acceptable carrier" means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a

- 30 -

human or other vertebrate animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.

The immunostimulatory oligonucleotides useful in the invention may be delivered in mixtures with additional adjuvant(s), other therapeutics, or antigen(s). A mixture may consist of several adjuvants in addition to the immunostimulatory oligonucleotide or several antigens or other therapeutics.

The particular mode selected will depend, of course, upon the particular adjuvants or antigen selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an immune response without causing clinically unacceptable adverse effects. Preferred modes of administration are discussed above.

The immunostimulatory oligonucleotides may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the immunostimulatory oligonucleotides into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, purpose of the immunization (i.e., prophylactic or therapeutic), nature and severity of the disorder, age and body weight of the patient, different doses may be necessary. The administration of a given dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units. Multiple administration of doses at specific intervals of weeks or months apart is usual for boosting the antigen-specific responses.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compounds,

increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di-and tri-glycerides; hydrogel release systems; sylvatic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

### Examples

#### Example 1. CpG-ODN Protects Mice from Scrapie Prion.

Groups of 8 mice each were inoculated intraperitoneally with 100  $\mu$ l of 10% brain homogenates from mice terminally ill with RML scrapie prion strain corresponding to an infectious challenge of approximately  $10^4$  LD<sub>50</sub>. The mice received 0.15 pmol (30  $\mu$ l of 5 nM solution) CpG-ODN (oligonucleotide 1826, 5'- TCCATGACGTTCTGACGTT -3', SEQ ID NO:18), which has been shown to be a strong inducer of innate immunity and to confer sterile immunity against certain infectious diseases. Sparwasser T et al. (2000) *Eur J Immunol* 30:3591-7. CpG-ODN was administered intraperitoneally at the time of inoculation (0h) with scrapie prions as well as 4 times at intervals of 24h (4 x q 24h); a second group received 0.15 pmol (30  $\mu$ l of 5 nM solution) CpG-ODN 7h after infection (7h) and 4 times at intervals of 24h (4 x q 24h); a third group received CpG-ODN at 7h after infection and subsequently 20 times at intervals of 24h (20 x q 24h). Controls matched for age and sex were given saline instead of CpG-ODN at the identical time intervals. Additional control experiments were also performed in uninfected mice using saline and brain homogenates of

- 32 -

uninfected mice. All animals were observed and scored daily for clinical signs of disease. Scrapie in mice is characterized by ataxia of gait, tremor, difficulty righting from a supine position, and tail rigidity. Occurrence of two of these four symptoms was used as the end point criterion for establishing a clinical diagnosis of scrapie. Western blots of brain homogenates were performed to confirm the diagnosis. All results were analyzed using the Student's t test (Table 1).

Table 1. Mean incubation time in C57BL/6 mice after inoculation with scrapie strain RML and treatment with CpG-ODN.

Group	Inoculation	Treatment	Regimen	Time to Terminal Disease (d) ± SD	Attack Rate
1	RML	CpG 1826	0h and 4 x q 24h	253 ± 4	8/8
2	RML	CpG 1826	7h and 4 x q 24h	250 ± 6	8/8
3	RML	CpG 1826	7h and 20 x q 24h	> 330 no disease	0/8
4	RML	Saline	0h and 4 x q 24h	183 ± 7	8/8
5	RML	Saline	7h and 4 x q 24h	181 ± 3	8/8
6	RML	Saline	7h and 20 x q 24h	181 ± 3	8/8
7	Saline	CpG 1826	0h and 4 x q 24h	No disease	0/8
8	Saline	CpG 1826	7h and 4 x q 24h	No disease	0/8
9	Saline	CpG 1826	7h and 20 x q 24h	No disease	0/8
10	Brain homogenate of uninfected mouse	CpG 1826	0h and 4 x q 24h	No disease	0/8
11	Brain homogenate of uninfected mouse	CpG 1826	7h and 4 x q 24h	No disease	0/8
12	Brain homogenate of uninfected mouse	CpG 1826	7h and 20 x q 24h	No disease	0/8

Mice infected with the RML strain which received CpG-ODN at the time of inoculation and 7h post-infection as well as 4 times at intervals of 24h showed a dramatic prolongation of survival time compared to control mice with an increase in survival time of 38% in both cases. These differences were highly significant ( $p<0.0001$ ). The application of CpG-ODN 7h post-inoculation and 20 times at 24h intervals led to disease-free intervals of more than 330 days. All control groups which were not inoculated with the RML strain remained disease-free, and no harmful effect of CpG-ODN application was observed.

- 33 -

These results showed that the application of CpG-ODN at the time of infection and 7h after infection led to a dramatic prolongation of survival time. This effect can be amplified when CpG-ODN are given for a longer period of time. The application of CpG-ODN for 20 times at 24h intervals results in a disease-free interval of >330 days, which indicates the great potential of CpG-ODN for post-exposure prophylaxis of people with exposure to infection. The mechanism of disease prevention remains to be determined, but it seems that the most likely explanation for this effect is a stimulation of TLR-expressing cells of the innate immune system, e.g., macrophages, monocytes, and especially dendritic cells. Sparwasser T et al. (2000) *Eur J Immunol* 30:3591-7. CpG-ODN has been known to induce resistance against other infectious diseases. Zimmermann S et al. (1998) *J Immunol* 160:3627-30. The induction of extreme prolongation of the incubation time or even resistance to prion disease was a surprising finding in the context of a completely different infectious agent.

The findings presented here show that administration of CpG-ODN prolongs the incubation time by 38% and may have the potential to prevent infection after repeated administration, even when high doses of infectivity are administered intraperitoneally. It may therefore be possible to prevent disease after inadvertent iatrogenic exposure with much lower infectious doses administered peripherally.

**Example 2. Effect of Timing Between Exposure to Prion and Administration of CpG-ODN.**

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1, except that the interval between injection with RML scrapie prion or control and administration of CpG-ODN or control is varied. In some groups administration of CpG-ODN is delayed as much as a month following injection with RML scrapie prion or control. In some groups administration of CpG-ODN precedes injection with RML scrapie prion or control. In some groups the number and schedule of repeated administrations of CpG-ODN is varied from Example 1. Results, measured as in Example 1, show that CpG-ODN is effective even when administered more than 7h after injection with RML scrapie prion.

**Example 3. Mice Protected from Scrapie Prion by CpG-ODN Develop an Immune Response to Prion.**

- 34 -

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1 or Example 2. At various time points following injection with RML scrapie prion or control and treatment with CpG-ODN or control, tissue or blood samples are obtained and analyzed for prion-specific and prion-nonspecific immune response. Presence of an immune response is determined by suitable method or measurement including, without limitation, antibody titer, enzyme-linked immunosorbent assay (ELISA), flow cytometry, cell proliferation assay, cytotoxicity assay, polymerase chain reaction (PCR) and reverse transcriptase-polymerase chain reaction (RT-PCR), Western immunoblot, Northern blot, and Southern blot. General methods for these types of measurements are standard and are suitably adapted to the specific antigen or stimulus being assayed. For example, ELISA is used to measure production of various secreted products, including antibodies, cytokines and chemokines. Cytokines and chemokines in this example include interleukin (IL)-4, IL-10, IL-6, IL-12, IL-18, interferon (IFN)- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , tumor necrosis factor (TNF), and IP-10. Flow cytometry is used to measure cell surface and intracellular proteins, including markers associated with immune cell activation. Markers associated with immune cell activation can vary with cell type but include cluster of differentiation (CD) markers such as CD86, major histocompatibility complex (MHC), inducible cytokine receptors, and certain costimulatory molecules. Results show that CpG-ODN induces an immune response to prion protein.

**Example 4. Selection of CpG-ODN.**

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1 or Example 2. Various CpG-ODN are compared against ODN 1826 for their effectiveness. Results, measured as in Example 1, show that protection is related to the use of species-optimized CpG-ODN.

**Example 5. Use of CpG-ODN in Alzheimer's Disease Model.**

Mice genetically susceptible to developing Alzheimer's-like disease are administered CpG nucleic acid alone or CpG nucleic acid plus antigen (e.g., amyloid precursor protein or A $\beta$ ), either prior to or following onset of Alzheimer's-like disease. Similar mice are administered appropriate control treatment. Animals are monitored for behavioral and histologic evidence of Alzheimer's-like disease.

- 35 -

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

We claim:

- 36 -

### Claims

1. A method for treating a prion disease in a subject, comprising:  
administering to a subject having or at risk of developing a prion disease a CpG nucleic acid in an effective amount to treat the prion disease.
2. The method according to claim 1, wherein the administering follows exposure of the subject to a prion protein that is associated with a prion disease.
3. The method according to claim 1, wherein the prion disease is a transmissible spongiform encephalopathy (TSE).
4. The method according to claim 1, wherein the prion disease is scrapie.
5. The method according to claim 1, wherein the prion disease is bovine spongiform encephalopathy (BSE).
6. The method according to claim 1, wherein the prion disease is variant Creutzfeldt-Jakob disease (vCJD).
7. The method according to claim 1, wherein the prion disease is iatrogenic Creutzfeldt-Jakob disease (iCJD).
8. The method according to claim 1, wherein the subject is a human.
9. A method for inducing an immune response to a prion protein, comprising:  
contacting an antigen-presenting cell (APC) with a prion protein; and  
contacting the APC with a CpG nucleic acid in an effective amount to induce an immune response to the prion protein.
10. The method according to claim 9, wherein the immune response is in vivo.

11. The method according to claim 9, wherein the APC is selected from the group consisting of: a B cell, a dendritic cell, a macrophage, and a monocyte.
12. The method according to claim 9, wherein the APC is a dendritic cell.
13. The method according to claim 9, wherein the APC expresses a Toll-like receptor (TLR) that signals in response to the CpG nucleic acid.
14. The method according to claim 13, wherein the TLR is TLR9.
15. The method according to claim 9, wherein the prion protein is prion protein:scrapie form (PrP<sup>Sc</sup>).
16. The method according to claim 9, wherein the prion protein is a fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup>.
17. The method according to claim 9, wherein the prion protein is a derivative of PrP<sup>Sc</sup> or a derivative of a fragment of PrP<sup>Sc</sup> lacking at least the amino terminus of full-length PrP<sup>Sc</sup>.
18. The method according to claim 9, wherein the CpG nucleic acid is a Class B CpG nucleic acid.
19. The method according to claim 9, wherein the CpG nucleic acid is a Class A CpG nucleic acid.
20. The method according to claim 9, wherein the CpG nucleic acid is a Class C CpG nucleic acid.
21. The method according to claim 9, wherein the CpG nucleic acid is optimized for use in a species of the subject.

## SEQUENCE LISTING

<110> Coley Pharmaceutical GmbH  
<120> USE OF CpG NUCLEIC ACIDS IN PRION DISEASE

<130> C01041.70038

<150> US 60/396,432  
<151> 2002-07-17

<160> 19

<170> PatentIn version 3.1

<210> 1  
<211> 2415  
<212> DNA  
<213> Homo sapiens

<400> 1  
cggcgccgag agtttctcctt ctcctcacga ccgaggcaga gcagtcatta tggcgaacct 60  
tggctgctgg atgctggttc tctttgtggc cacatggagt gacctgggcc tctgcaagaa 120  
gcgcggaaag cctggaggat ggaacactgg gggcagccga taccggggc agggcagccc 180  
tggaggcaac cgctacccac ctcagggcgg tggctggctgg gggcagcctc atggtggtgg 240  
ctggggcag cctcatggtg gtggctgggg gcagccccat ggtggtggt ggggacagcc 300  
tcatggtggt ggctgggtc aaggaggtgg caccacagt cagtggaaaca agccgagtaa 360  
gcacaaaaacc aacatgaagc acatggctgg tgctgcagca gctggggcag tggtgggggg 420  
ccttggcggc tacatgctgg gaagtgcacat gagcaggccc atcatacatt tcggcagtga 480  
ctatgaggac cgttactatc gtgaaaacat gcaccgttac cccaccaag tgtactacag 540  
gccccatggat gactacagca accagaacaa ctttgcac gactgcgtca atatcacaat 600  
caaggcagcac acggtcacca caaccaccaa gggggagaac ttcaccgaga ccgacgttaa 660  
gatgatggag cgctgggttg agcagatgtg tatcacccag tacgagaggg aatctcaggc 720  
ctattaccag agaggatcga gcatggctctt cttctctctt ccacctgtga tcctcctgtat 780  
ctcttccttc atcttcctga tagtggatg aggaaggctt tcctgttttc accatcttcc 840  
taatctttt ccagcttgag ggaggcggta tccacctgca gcccttttag tggtggtgtc 900  
tcactctttc ttctctcttt gtcccgata ggctaatcaa tacccttggc actgatggc 960  
actggaaaaac atagagttaga cctgagatgc tggtaagcc cccttgatt gagttcatca 1020  
tgagccgttg ctaatgccag gccagtaaaa gtataacagc aaataaccat tggtaatct 1080  
ggacttattt ttggacttag tgcaacaggt tgaggctaaa acaaatctca gaacagtctg 1140

aaataccctt gcctggatac ctctggctcc ttcagcagct agagctcagt atactaatgc	1200
cctatcttag tagagatttc atagctattt agagatattt tccatTTAA gaaaACCCGA	1260
caacatttct gccaggTTTg ttaggaggcc acatgatact tattcaaaaa aatcctagag	1320
attcttagct cttgggatgc aggctcagcc cgctggagca tgagctctgt gtgtaccgag	1380
aactgggtg atgtttact tttcacagta tgggctacac agcagctgtt caacaagagt	1440
aaatattgtc acaacactga acctctggct agaggacata ttcacagtga acataactgt	1500
aacatataatg aaaggcttct gggacttcaa atcaaATGTT tggaaatggt gcccTTggag	1560
gcaacccccc attttagatg tttAAaggac cctatatgtg gcattcctt cttAAacta	1620
taggttaatta aggcaGCTGA aaagtaaattt gccttctaga cactgaaggc aaatctcctt	1680
tgtccattt cctggaaacc agaatgattt tgacatacag gagagctgca gttgtgaaag	1740
caccatcatc atagaggatg atgttaattt AAAATGGTCA gtgtgcaaag AAAAGAACTG	1800
cttgcattt tttatttctg tctcataatt gtcaAAACC agaatttaggt caagttcata	1860
gtttctgtaa ttggctttt gatcaaAGAA tagggagaca atctaaaaaa tatcttaggt	1920
tggagatgac agaaatatga ttgatttcaa gtggaaaaag aaattctgtt aatgttaatt	1980
aaagtaaaat tattccctga attgttttattt attgtcacct agcagatatg tattactttt	2040
ctgcaatgtt attattggct tgcactttgt gagtatctat gtAAAAATAT atatgtatat	2100
aaaatataat ttgcataAGGA cagacttagg agtttGTTT agagcagtta acatctgaag	2160
tgtctaatgc attaactttt gtaaggTact gaatacttaa tatgtggaa accctttgc	2220
gtggcctta ggcttacaat gtgcactgaa tcgtttcatg taagaatCCA aagtggacac	2280
cattaacagg tctttgaaat atgcATgtac tttatTTT ctatatttGT aactttGcat	2340
gttcttGTT tgTTatataa AAAAATTGTA aatgttaat atctgactga aattaaacga	2400
gcgaagatga gcacc	2415

<210> 2  
 <211> 2446  
 <212> DNA  
 <213> Mustela sp.

<400> 2	
tcattttgtt ttgtttgtt ttgtttgcag ataagccatc atggtaaaaa gcccacatagg	60
cagctggctc ctggTTCTCT ttgtggccac atggagtgac attggcttct gcaagaAGCG	120
gccaaAGCCT ggaggaggct ggaacactgg ggggagCCGA tacccaggGC agggcAGTCC	180
tggaggcaac cgctacCCAC cccaggGTgg tggcggctgg ggccAGCCCC acggggGTgg	240

ctggggacag ccccacgggg gtggctgggg tcagccccac gggggtgtggct ggggacagcc	300
gcatggtggc ggtggctggg gtcaagggtgg tgggagccac ggtcagtggg gcaagcccaag	360
taagccaaa accaacatga agcatgtggc gggagccgca gcagccgggg cggtcgtggg	420
gggcctggc ggctacatgc tggggagcgc catgagcagg cccctcattc attttggcaa	480
cgactatgag gaccgctact accgtgagaa catgtaccgc taccacaacc aagtgtacta	540
caagccgtg gatcagtaca gcaaccagaa caacttcgtg catgactgcg tcaacatcac	600
ggtcaagcag cacacggtga ccaccaccac caagggcgag aacttcacgg agaccgacat	660
gaagatcatg gagcgcgtgg tggagcagat gtgtgtcacc cagtaccagc gagagtccga	720
ggcttactac cagagggggg cgagcgcacat cctcttctcg cccctcccg tgatcctct	780
catctcactg ctcattctcc tgatagtggg atgaggatgg cttcccatt ctctccatcg	840
tcttcacctt ttacaggttg ggggaggggg tgtctaccta cagccctgtta gtgggttgt	900
ctcattcctg cttctttta tcacccatag gctaatcccc ttggccctga tggccctggg	960
aaatgttagag cagacccagg atgctattta ttcaagcccc catgtgttgg agtccttcag	1020
ggccaaatgc tagtgcaggg ctgagaataa cagcaaatca tcattggttg acctagggt	1080
gctttttgt tggtgtgtc tagtgcagct gaccgaggct aaaacaattc tcaaaacagt	1140
tttcaaatac cttgcctgg aaacctctgg ctcctgctgc agctagagct cagtacatta	1200
atgtcccatc tttagccgtgt cttcatagca acttggggaa gttttctcc ccactctaaa	1260
agaacgcgat tgcacttccc tgtgcaaaga acatttctgc caaatttcaa aggaggccac	1320
atgatattca ttcaaaaagc aaaactagaa accctttgtt cttggacgca agccggcct	1380
gctaggagca ccaaactggg gcgatggtt gcattctgcg gcgtggctta tgccgcagcc	1440
gaggtgtcca gcgtaaatat tgatgcgacg ctagacctag gcagaggatg tttgcacagg	1500
gaatgaacat aatcaacagt gcgaaaatgc tacaaaaat cccacactgg ggagcagtgt	1560
ccttggaggc aagtttttt cttttggga cattaaagc ccctatatgt ggcattcctt	1620
tcttcgtaa cctaaactat agataattaa ggcagttaaa aattgaactt cttccaggc	1680
cccaagagca aatctttgtt cacttacctg gaaaccagaa tgattttgac acagaggaag	1740
gtgcagctgt taaaataacc ctcatcttag aagatgcacat catggagaaa acgatccgt	1800
gacaaaaatg atcgcatttc ttcattgctg tctcgtaatt gacagaaaacc agaattatgt	1860
caagtccctag tttctataat cagttttga atcaaagaat ggaagtccat ccaaaaaaaaa	1920
aaaagaaata ctttaggtca cccatgacag aaataccat tcaggttaga aaaaaggaat	1980
tctgttaact gttatccaag taaggcaaaa ttattgtccg gattgttca tatcatcagc	2040

tagcagataa attagcattc tgcaatgttc cggcggca ctgtgcgggt atttgatgtt	2100
aaaaaaaaatt attatatata ttgtgtatga caaacttaga agttttgct agaggagtt	2160
acatctgata tatctaattgc accaccagg ttggaaaggta ctaaataactt aatatgtaga	2220
aatcctttg cgtggcctc aggcttacac gtgcactgaa tagtttgta ttagatagcc	2280
catgtggctc tcgaaatatg catgtacttt atatttcta tatttgtaac tgggcatgt	2340
cttgtataaa aaatgtataa acattcgaac tcttgactag aattaaacag gaactgagtg	2400
tgtccccatgt gtttgcagtg acattcacca ccgcaccctg tgggg	2446

<210> 3  
 <211> 810  
 <212> DNA  
 <213> *Mesocricetus auratus*

<400> 3	
tcgaaaatct ccctcttag caatttcttg ctccatgtt ttcagcaatt gctttctcg	60
tccatttaggc aacctttcat tttctcacct tcccattat gtaacgggag caatgggttc	120
tggaccagtc ttccattaaa gatgatttt atagtcggtg agcgccgtca gggagtgatg	180
acacctgggg gcggtttaaa ccgtacaatc cttaaacca gtctggagcg gtgactcatt	240
tccccaggga gaagtggcgc ggccattggg gagcacgacg caagccccgc cccaccacgc	300
ccggccccgc cctgctaccc ctccctgactc actgccccgc ccgtcccccc gcggcgtccg	360
agcagcagac cgagaaggca catcgagtcc actcgatcg tcgggtggcag gtaagcggct	420
tctgaagcct ggcccccggga agggtgctgg agccaggcct cggttaagcct tcggcttccc	480
agagccaage ccggcttact ccggctctcg gggcgctgag gccgcggggc tgaggttgag	540
tctggctggg aggtgaccgc gcacccgcag ccgcgcgtct ctttggggca ccgaacccca	600
ggagaggcca ggagccatcc ctccctcccg agccggctc acccccagag tcgctcgaaa	660
atggggatg gggatgggg tggcatctt tggactgtcg tttgtgtttt cttctcttt	720
tgtatagct acacgcaaca taatttacc cagggttcca ccgtggtctc gtccgtcctc	780
ggcatctctc agtccagtgac atacccaagg	810

<210> 4  
 <211> 4020  
 <212> DNA  
 <213> *Ovis aries*

<400> 4	
atggtgaaaa gccacatagg cagttggatc ctgggtctct ttgtggccat gtggagtgac	60

gtgggcctct gcaagaagcg accaaaacct ggccggaggat ggaacactgg ggggagccga	120
tacccgggac agggcagtcc tggaggcaac cgctatccac ctcagggagg gggtggctgg	180
ggtcagcccc atggaggtgg ctggggccaa cctcatggag gtggctgggg tcagccccat	240
ggtggtggct gggacagcc acatggtgtt ggaggctggg gtcaaggtgg tagccacagt	300
cagtggaaaca agccagtaa gccaaaaacc aacatgaagc atgtggcagg agctgctgca	360
gctggagcag tggtaggggg ctttggtggc tacatgctgg gaagtgccat gagcaggcct	420
tttatacatt ttggcaatga ctatgaggac cgttactatc gtggaaacat gtaccgttac	480
cccaaccaag tgtactacag accagtggat cagtagatgta accagaacaa ctttgtgcat	540
gactgtgtca acatcacagt caagcaacac acagtcacca ccaccaccaa gggggagaac	600
ttcaccgaaa ctgacatcaa gataatggag cgagtggtgg agcaaatgtg catcacccag	660
taccagagag aatcccaggc ttattaccaa aggggggcaa gtgtgatcct ctttttttcc	720
cctcctgtga tcctcctcat ctcttcctc attttctca tagtaggata ggggcaacct	780
tcctgtttc attatcttct taatcttgc caggtgggg gagggagtgt ctacctgcag	840
ccctgttagt gtgggtgtc atttcttgcatt tctctttgt tacctgtata ataataccct	900
tggcgcttac agcaactgggaa aatgacaagc agacatgaga tgctgtttat tcaagtcacca	960
tttagctcaatgt cccatcttag cagtatttt gtagcaattt tctcatttgt	1020
ttcaagaaca cctgactaca tttccctttg ggaatagcat ttctgccaag tctggaaagga	1080
ggccacataa tattcattca aaaaaacaaa actggaaatc cttagttcat agacccaggg	1140
tccaccctgt tgagagcatg tgcctgtgt ctgcagagaa ctataaagga tattctgcatt	1200
tttgcaggat acatttgcag gtaacacagc catctattgc atcaagaatg gatattcatg	1260
caaccccttgc cttatggca gaggacatct tcacaaggaa tgaacataat acaaaggctt	1320
ctgagactaa aaaattccaa catatggaaag aggtgccctt ggtggcagcc ttccattttg	1380
tatgtttaaag caccattcaag tgatattcct ttcttttagta acataaagta tagataatta	1440
aggtacccatc attaaactac cttctagaca ctgagagcaa atctgttgg tatctggAAC	1500
ccaggatgttttgc cttagggatg tgagagttgg actgtaaaga aagctgagtg	1560
ctgaagagtt catgcttttgc aactatagtg ttggagaaaa ctcttgagag tcccttggac	1620
tgaaaggaga tcagtcctga atattcatttgc gaaggactga tgctgaagct gaaactccaa	1680
tactttggtc acctgtatggg aagaactgaa ggcaggaggg atgcttaggaa agactgaagg	1740
caggaggaga aggggacgac agaggatgag atggctagat ggcatcatgg actcaatggaa	1800
catgagctta agtaaactcc aggagttggc aatggacagg gagacctggc gtcctgcagt	1860

ccatgggtgc gcagagtcgg acacgattga gtgactaaat tgaggtgacc cagatttaac 1920  
atagagaatg cagatacataaa actcatattc atttgattga atctttcct gaaccagtgc 1980  
tagtgttggc ctggtaaggg tataacagca tatatagggt atgtgatgaa gagatagtgt 2040  
acatgaaata tgtgcatttc tttattgctg tcttataatt gtcaaaaaag aaaatttagt 2100  
ccttggtttc tgtaaaattt acttgaatca aaaggaggc atttaaagaa ataaatttaga 2160  
gatgatagaa atctgatcca ttcagagtag aaaaagaaaat tccattactg ttattaaaga 2220  
aggtaaaattt attccctgaa ttgttcaata ttgtcaccta gcagatagac actattctgt 2280  
actgtttta ctagcttgca ccttggta tcctatgtaa aaacatattt gcatatgaca 2340  
aacttttct gtttagagcaa ttaacatctg aaccaccta tgcattacct gttttgtaa 2400  
ggtactttt gtaaggtact aaggagatgt gggttaatc cctaggtcag gtaaatcccc 2460  
tagaggaaga aatggcaacc cactccagta ttcttgccag gaaaatccag tggcagagg 2520  
agcctggcag ggtacagtct aagagcatgg gttgcaaag agtgagacaa gacttgagct 2580  
actgaacaat aaggacaata aatgctgggt cggctaaaag gttcatttagg tttttttct 2640  
gtaagatggc tctagtagta cttgtttta tcttcattcg aaacaatttt gtttagattgt 2700  
atgtgacagc tcttgatca gcatgcattt gaaaaaaca tcacaattgg taaatttttg 2760  
tatagccatc ttactattga agatggaaga aaagaagcaa aattttcagc atatcatgct 2820  
gtacttattt caagaaagat aaccaaaaatg caaaaatgta tttgtgaagt gtatggagaa 2880  
ggggctgcaa ctgatcaagc ttgtcaaagt agtttgaa gtttcgtct ggagatttct 2940  
tattggacga tgctccacag ttggatatac cagttgaagt tgatagtgtat caaattgaga 3000  
tattgagaat aatcgatgtt ataccacgct ggagatagct gacatactca aaatatccaa 3060  
atagaacattt gaaaaccatt tgcaccatct cagttatgtt aatcactttt atgtttgagt 3120  
tccacataag caaaaaaca acaacaaaaa aaaatacaac cttgaccata tttgcgcatt 3180  
cagttctcta ctgaaatgat tgaaaacact ttgttttaa aaacagattt tgattaacag 3240  
tgggtacgt acaataacgt agatggaaga aattttaggg tgagcaaat gaaccacacc 3300  
accaaaggcc agtcttcctc taaaagaagat gtgttatgg tgggattgg aagtaatcct 3360  
ctattatggc ttcttctgga aaacactgct cctaatttgc ccaactgaaa acagcactca 3420  
acgaaaagca tccagaattt gtcaatagaa aacataatct tccatcaggta taacgcaaga 3480  
ctacatattt ctttgatgac ccagcatggc tggagttct gattcatctg ttgtattcag 3540  
acggttgcattt ttggatattt ttccattttt ttcagttctc aaaattatca taatggaaaa 3600

aatttccatt cccttggaaaga	tgtaaaagtgc	atctggaaaa	tttctttgct	caaaaagata	3660	
aaaagtttg	tgaacacaga	attatgacgt	tgcctgaaaa	atggcagaag	gtagtggAAC	3720
aaaagagtga	ctatgttgtt	tggtaaagg	tttagtgaaa	atgaaaaatg	tgtctttat	3780
ttttattaa	acaccaaagg	cacatTTAG	caacccaata	ctgaatctaa	aggaaactct	3840
tctgtgtt	gtccttacag	tgtgcactga	tagttgtat	aagaatccag	agtgtatTTT	3900
gaaatacga	tgtgcttata	tttttatata	ttgtaaCTTT	gcatgtactt	gttttgtt	3960
aaaagtttat	aatatTTAA	tatctgacta	aaattaaaca	ggagctaaaa	ggagtatctt	4020

<210> 5  
<211> 795  
<212> DNA  
<213> Bos taurus

<400> 5	atggtaaaaa	gccacatagg	cagttggatc	ctggTTCTCT	ttgtggccat	gtggagtgac	60
gtgggcctct	gcaagaagcg	acccaaacct	ggaggaggat	ggaacactgg	ggggagccga	120	
tacccaggac	agggcagtcc	tggaggcaac	cgttatccac	ctcagggagg	gggtggctgg	180	
ggtcagcccc	atggaggtgg	ctggggccag	cctcatggag	gtggctgggg	ccagcctcat	240	
ggaggtggct	ggggtcagcc	ccatggtggt	ggctggggac	agccacatgg	ttgtggaggc	300	
tgggtcaag	gtggtaccca	cggtaatgg	aacaaaccca	gtaagccaaa	aaccaacatg	360	
aagcatgtgg	caggagctgc	tgcagctgga	gcagtggtag	ggggccttgg	tggctacatg	420	
ctgggaagtg	ccatgagcag	gcctttata	cattttggca	gtgactatga	ggaccgttac	480	
tatcgtaaaa	acatgcacccg	ttaccccaac	caagtgtact	acaggccagt	ggatcagtat	540	
agtaaccaga	acaactttgt	gcatgactgt	gtcaacatca	cagtcaagga	acacacagtc	600	
accaccacca	ccaaggggga	gaacttcacc	gaaactgaca	tcaagatgtat	ggagcgagtg	660	
gtggagcaaa	tgtgcattac	ccagtaccag	agagaatccc	aggcttatta	ccaacgaggg	720	
gcaagtgtga	tccttttctc	ttcccccctt	gtgatcctcc	tcatctttt	cctcattttt	780	
ctcatagtag	gatag					795	

<210> 6  
<211> 2188  
<212> DNA  
<213> Gallus gallus

<400> 6	gaattccctc	ggcagccagc	tcctccctct	cgctatTTAT	tcctttctcc	ccccccctacg	60
ctggatctgg	atcatctcaa	gccgagcggt	gacggcttct	tggatcgctc	atacataaaat	120	

atctgtgagt cagaggaagc aaccaccgac cccaagacct caccggagc catggctagg	180
ctcctcacca cctgctgcct gctggccctg ctgctgcgg cctgcaccga cgtcgcctc	240
tccaaagaagg gcaaaggcaa acccagtggt gggggttggg ggcggggag ccatacgccag	300
cccagctacc cccgccagcc gggctaccct cataaccag ggtacccca taaccaggg	360
taccccaaca accctggcta tccccataac cccggctacc cccagaaccc tggctacccc	420
cataaccag gttacccagg ctggggtcaa ggctacaacc catccagcgg aggaagttac	480
cacaaccaga agccatggaa accccccc accaacttca agcacgtggc gggggcagca	540
gcggcgggtg ctgtggtggg gggcttgggg ggctacgcca tggggcgcgt tatgtcaggg	600
atgaactacc acttcgatag acccgatgag taccgatggt ggagtgagaa ctggcgcgt	660
tatcccaacc gggttacta ccgggattac agcagccccg tgccacagga cgtcttcgtg	720
gccgattgct ttaacatcac agtactgag tacagcattg gcccctgctgc caagaagaac	780
acctccgagg ctgtggcggc agcaaaccaa acggaggtgg agatggagaa caaagtggtg	840
acgaaggta tccgcgagat gtgcgtgcag cagtaccgcg agtaccgcct ggccctggc	900
atccagctgc accctgctga cacctggctc gccgtctcc tccctctctt caccaccctt	960
tttgcctatgc actgatggga tgccgtgccc cggccctgtg gcagtgagat gacatgtgt	1020
ccccgtgccc acccatgggg tggcccttgt cctcgcttt gtccatctt ggtgaagatg	1080
tccccccgtc gcctccccgc aggctctgtat ttggcaaat gggagggat tttgtcttgt	1140
cctggcgtg gcaggacggc tgctgggtggt ggagtggat gccccaaaaaa tggccttcac	1200
cacttcctcc tcccttcct ttctggggcg gagatatggg ctgcgtccagc ccttattgtc	1260
cctgcaagag cgtatctgaa aatcctcttt gctaacaagc agggttttac ctaatctgt	1320
tagccccagt gacagcagag cgccttccc cagggcacac caaccccaag ctgaggtgt	1380
tggcagccac acgtcccatg gaggctgatg gttttgggg cgtcccaagc aacaccctgg	1440
gctactgagg tgcaattgtat gctctttat ctgcctatcc caaccctacc gtgttagatag	1500
gaactgcctg ctctgcattt tgcatgctgc aaacacccctcc tgccgcagcg cccccaaaaat	1560
agagtgattt gggatagtg aggctgaagc cacagcagct tgggattggg ctcatcatat	1620
caatccatga tgctttgctt ccagctgagc ctcactgccc tttttagcc tgcccagagg	1680
aagggagcgc tgctaaatgc ccaaaaaggt aacactgagc aaaagcttat ttcaatgtat	1740
gatagagaac gagtgcatct cgcacagatc agccatggga gcatcgttt ccatcagccc	1800
caaaacccaa aggatgctaa aatgcagccaa aagggaaatc aagcacgcag ggaaggactt	1860

gaatcagctc aactggattg aaatggcaaa aggcatgagt agaacgaacg gcaagggat	1920
gctggagatc cacccctgt gagcaaattt ttcgatgcag ccaatggAAC tattgcttct	1980
tgtgcttcag ttgctgctga tgtgtacata ggctgttagca tatgtaaagt tacacgtgtc	2040
aagctgctcg caccgcgtag agctaatacg tatcatgtat gtgggcactg aatgccacgg	2100
ttggccatac ccaaccgtcc taaacgattt tcacgtcgct gtaacttaag tggagataca	2160
ctttcagttt attcagcaaa aggaattc	2188

<210> 7  
 <211> 2097  
 <212> DNA  
 <213> Mus musculus

<400> 7	
aattccttca gaactgaacc atttcaaccg agctgaagca ttctgccttc ctatgtggta	60
cagtccaaatt taggagagcc aagcagacta tcagtcatca tggcgaaccc tggctactgg	120
ctgctggccc tctttgtgac tatgtggact gatgtcgcc tctgcaaaaaa gcgccaaag	180
cctggagggt ggaacacccgg tggaaagccgg tatccccggc agggaaagccc tggaggcaac	240
cgttaccac ctcaggggtgg cacctggggg cagccccacg gtggggctg gggacaaccc	300
catggggca gctggggaca acctcatggt ggtagttttt gtcagccccaa tggcggtgga	360
tggggcaag gaggggggtac ccataatcag tggaaacaagc ccagcaaacc aaaaaccaac	420
ctcaagcatg tggcaggggc tgcggcagct gggcagtag tggggggct tggtggtac	480
atgctgggaa gcgccgtgag caggccatg atccatttt gcaacgactg ggaggaccgc	540
tactaccgtg aaaacatgta ccgctaccct aaccaagtgt actacaggcc agtggatcag	600
tacagcaacc agaacaactt cgtgcacgac tgcgtcaata tcaccatcaa gcagcacacg	660
gtcaccacca ccaccaaggg ggagaacttc accgagaccc atgtgaagat gatggagcgc	720
gtgggtggagc agatgtgcgt caccctgatc cagaaggagt cccaggccta ttacgacggg	780
agaagatcca gcagcacccgt gctttctcc tccccctcgt tcatcctcct catctccttc	840
ctcatcttcc tgatcgtggg atgagggagg cttctgtgt tggcttcgtt cattctcg	900
gtctaggctg gggaggggt tatccacctg tagctttc aattgaggtt gttctcatc	960
ttgcttctct gtgtccccca taggctaata cccctggcac tggatggccc tggaaatgt	1020
acagtagacc agttgctt tgcgtcggtt cccttgcgtt gagtctgtca tcagccagtg	1080
ctaacaccgg gccaataaga atataacacc aaataactgc tggctagttt gggctttgtt	1140
ttggtcttagt gaataaatac tgggtatcc cctgacttgc acccagagta caaggtgaca	1200

gtgacacatg taacttagca taggcaaagg gttctacaac caaagaagcc actgtttggg	1260
gatggcgccc tggaaaacag cctcccacct gggatagcta gagcatccac acgtggaatt	1320
ctttcttac taacaaacga tagctgattg aaggcaacaa aaaaaaaaaa atcaaattgt	1380
cctactgacg ttgaaagcaa acctttgttc attcccaggg cactagaatg atcttagcc	1440
ttgcttggat tgaacttagga gatcttgact ctgaggagag ccagccctgt aaaaagctg	1500
gtcctcctgt gacgggaggg atggtaagg tacaaggct agaaacttga gtttcttcat	1560
ttctgtctca caattatcaa aagctagaat tagcttctgc cctatgttgc tgtaattcta	1620
tttgaactgg ataacagaga gacaatctaa acattctt aggctgcaga taagagaagt	1680
aggctccatt ccaaagtggg aaagaaattc tgctagcatt gtttaatca ggcaaaattt	1740
gttcctgaag ttgctttta ccccagcaga cataaactgc gatagcttca gttgcactg	1800
tggatttct gtatagaata tataaaacat aacttcaagc ttatgtctt ttttaaaac	1860
atctgaagta tggacgccc tggccgttcc atccagtact aatgcttac cgtgtgaccc	1920
ttggccttc agcgtgcact cagttccgtt ggattccaaa gcagacccct agctggctt	1980
tgaatctgca tgtacttcac gtttctata tttgttaactt tgcatgtatt ttgtttgtc	2040
atataaaaag tttataaaatg tttgtatca gactgacatt aaatagaagc tatgatg	2097

<210> 8  
 <211> 803  
 <212> DNA  
 <213> Ovis aries

<400> 8	
gcagagaagt catcatggtg aaaagccaca taggcagttg gatcctgggt ctctttgtgg	60
ccatgtggag tgacgtgggc ctctgcaaga agcgacccaa acctggcgga gnatggaaaca	120
ctggggggag ccgatacccg ggacagggca gtcctggagg caaccgctat ccacccctagg	180
gaggggggtgg ctggggtcag cccatggag gtggctgggg ccaacccat ggaggtggct	240
gggggtcagcc ccattgggtggt ggctggggac agccacatgg tggtgagggc tggggtcaag	300
gtggtagcca cagtcagtgg aacaagccca gtaagccaaa aaccaacatg aagcatgtgg	360
caggagctgc tgcagctgga gcagtggtag gggcccttgg tggctacatg ctggaaagtg	420
ccatgagcag gcctttata cattttggca atgactatga ggaccgttac tatcgtgaaa	480
acatgtaccc ttaccccaac caagtgtact acagaccagt ggatcgttat agtaaccaga	540
acaactttgt gcatgactgt gtcaacatca cagtcagca acacacagtc accaccacca	600
ccaaggggga gaacttcacc gaaactgaca tcaagataat ggagcgagtg gtggagccaa	660

tgtgcacac ccagtaccag agagaatccc aggcttatta ccaaaggggg gcaagtgtga	720
tcctctttc ttccccctcc gtgatcctcc tcatctctt cctcattttt ctcatagtag	780
gataggggca accttcctgt ttt	803

<210> 9  
 <211> 765  
 <212> DNA  
 <213> **Rattus norvegicus**

<400> 9 atggcgaacc ttggctactg gctgctggcc ctctttgtga ctacatgtac tgatgttggc	60
ctctgcaaaa agcggccaaa gcctggaggg tggaacactg gtggaagccg gtaccctggg	120
cagggaaagcc ctggaggcaa ccgttaccca cctcagactg gtggcacctg gggcagccc	180
catggtggtg gctggggaca acctcatggt ggtggctggg gacaacctca tggtggtggc	240
tgggtcagc cccatggcgg gggctggagt caaggagggg gtacccataa tcagtggaac	300
aagcccagca agccaaaaac caacctaag catgtggcag gggctgccgc agctggggca	360
gtagtgaaaa gccttggtgg ctacatgtt gggagtgcc a tagcaggcc catgtccat	420
tttggcaacg actgggagga ccgctactac cgagaaaaaca tgtaccgtta ccctaaccaa	480
gtgtactaca ggccgggtgga tcagtagc aaccagaaca acttcgtgca cgactgtgtc	540
aatatcacca tcaagcagca tacagtcacc accaccacca agggggagaa cttcacggag	600
accgacgtga agatgatgga gcgtgtggtg gagcagatgt gcgtcaccacca gtatcagaag	660
gagtcccagg cctattacga cgggagaaga tctagcgccg tgctttctc ctccccctct	720
gtgatcctcc tcatctcctt cctcatcttc ctgatcgtgg gatga	765

<210> 10  
 <211> 253  
 <212> PRT  
 <213> **Homo sapiens**

<400> 10

Met Ala Asn Leu Gly Cys Trp Met Leu Val Leu Phe Val Ala Thr Trp					
1	5		10		15
	10				
	15				

Ser Asp Leu Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly Trp Asn			
20	25		30
	30		

Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg			
35	40		45
	45		

Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly  
 50 55 60

Trp Gly Gln Pro His Gly Gly Trp Gly Gln Pro His Gly Gly Gly  
 65 70 75 80

Trp Gly Gln Pro His Gly Gly Trp Gly Gln Gly Gly Gly Thr His  
 85 90 95

Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met Lys His Met  
 100 105 110

Ala Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr  
 115 120 125

Met Leu Gly Ser Ala Met Ser Arg Pro Ile Ile His Phe Gly Ser Asp  
 130 135 140

Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met His Arg Tyr Pro Asn Gln  
 145 150 155 160

Val Tyr Tyr Arg Pro Met Asp Glu Tyr Ser Asn Gln Asn Asn Phe Val  
 165 170 175

His Asp Cys Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr  
 180 185 190

Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg  
 195 200 205

Val Val Glu Gln Met Cys Ile Thr Gln Tyr Glu Arg Glu Ser Gln Ala  
 210 215 220

Tyr Tyr Gln Arg Gly Ser Ser Met Val Leu Phe Ser Ser Pro Pro Val  
 225 230 235 240

Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly  
 245 250

<210> 11  
 <211> 263  
 <212> PRT  
 <213> Bos taurus

<400> 11

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala  
 1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly  
 20 25 30

Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly  
 35 40 45

Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His Gly  
 50 55 60

Gly Gly Trp Gly Gln Pro His Gly Gly Trp Gly Gln Pro His Gly  
 65 70 75 80

Gly Gly Trp Gly Gln Pro His Gly Gly Trp Gly Gln Pro His Gly  
 85 90 95

Gly Gly Gly Trp Gly Gln Gly Gly Thr His Gly Gln Trp Asn Lys Pro  
 100 105 110

Ser Lys Pro Lys Thr Asn Met Lys His Val Ala Gly Ala Ala Ala Ala  
 115 120 125

Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met  
 130 135 140

Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp Arg Tyr Tyr  
 145 150 155 160

Arg Glu Asn Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val  
 165 170 175

Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile  
 180 185 190

Thr Val Lys Glu His Thr Val Thr Thr Thr Lys Gly Glu Asn Phe  
 195 200 205

Thr Glu Thr Asp Ile Lys Met Met Glu Arg Val Val Glu Gln Met Cys  
 210 215 220

Val Thr Gln Tyr Gln Lys Glu Ser Gln Ala Tyr Tyr Asp Gln Gly Ala  
 225 230 235 240

Ser Val Ile Leu Phe Ser Ser Pro Pro Val Ile Leu Leu Ile Ser Phe  
 245 250 255

Leu Ile Phe Leu Ile Val Gly  
 260

<210> 12  
 <211> 264  
 <212> PRT  
 <213> Bos taurus

<400> 12

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala  
 1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly  
 20 25 30

Gly Trp Asn Thr Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly  
 35 40 45

Gly Asn Arg Tyr Pro Pro Gln Gly Gly Trp Gly Gln Pro His  
 50 55 60

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Trp Gly Gln Pro His  
 65 70 75 80

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Trp Gly Gln Pro His  
 85 90 95

Gly Gly Gly Trp Gly Gln Gly Thr His Gly Gln Trp Asn Lys  
 100 105 110

Pro Ser Lys Pro Lys Thr Asn Met Lys His Val Ala Gly Ala Ala Ala  
 115 120 125

Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala  
 130 135 140

Met Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp Arg Tyr  
 145 150 155 160

Tyr Arg Glu Asn Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro  
 165 170 175

Val Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn  
 180 185 190

Ile Thr Val Lys Glu His Thr Val Thr Thr Thr Lys Gly Glu Asn  
 195 200 205

Phe Thr Glu Thr Asp Ile Lys Met Met Glu Arg Val Val Glu Gln Met  
 210 215 220

Cys Ile Thr Gln Tyr Gln Arg Glu Ser Gln Ala Tyr Tyr Gln Arg Gly  
 225 230 235 240

Ala Ser Val Ile Leu Phe Ser Ser Pro Pro Val Ile Leu Leu Ile Ser  
 245 250 255

Phe Leu Ile Phe Leu Ile Val Gly  
 260

<210> 13  
 <211> 255  
 <212> PRT  
 <213> Ovis aries

<400> 13

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala  
 1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly  
 20 25 30

Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly  
 35 40 45

Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His Gly  
 50 55 60

Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His Gly  
 65 70 75 80

Gly Ser Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Gly Gly  
 85 90 95

Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met Lys  
 100 105 110

His Val Ala Gly Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly  
 115 120 125

Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu Ile His Phe Gly  
 130 135 140

Asn Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr Pro  
 145 150 155 160

Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn Asn  
 165 170 175

Phe Val His Asp Cys Val Asn Ile Thr Val Lys Gln His Thr Val Thr  
 180 185 190

Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Ile Lys Ile Met  
 195 200 205

Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln Tyr Gln Arg Glu Ser  
 210 215 220

Gln Ala Tyr Tyr Gln Arg Gly Ala Ser Val Ile Leu Phe Ser Ser Pro  
 225 230 235 240

Pro Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly  
 245 250 255

<210> 14  
 <211> 256  
 <212> PRT  
 <213> Ovis aries

<400> 14

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala  
 1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly  
 20 25 30

Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly  
 35 40 45

Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His  
 50 55 60

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His  
 65 70 75 80

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Gly  
 85 90 95

Gly Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met  
 100 105 110

Lys His Val Ala Gly Ala Ala Ala Gly Ala Val Val Gly Gly Leu  
 115 120 125

Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu Ile His Phe  
 130 135 140

Gly Asn Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr  
 145 150 155 160

Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn  
 165 170 175

Asn Phe Val His Asp Cys Val Asn Ile Thr Val Lys Gln His Thr Val  
 180 185 190

Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Ile Lys Ile  
 195 200 205

Met Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln Tyr Gln Arg Glu  
 210 215 220

Ser Gln Ala Tyr Tyr Gln Arg Gly Ala Ser Val Ile Leu Phe Ser Ser  
 225 230 235 240

Pro Pro Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly  
 245 250 255

<210> 15  
 <211> 254  
 <212> PRT  
 <213> *Mus musculus*

<400> 15

Met Ala Asn Leu Gly Tyr Trp Leu Leu Ala Leu Phe Val Thr Met Trp  
 1 5 10 15

Thr Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly Trp Asn  
 20 25 30

Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg  
 35 40 45

Tyr Pro Pro Gln Gly Gly Thr Trp Gly Gln Pro His Gly Gly Gly Trp  
 50 55 60

Gly Gln Pro His Gly Gly Ser Trp Gly Gln Pro His Gly Gly Ser Trp  
 65 70 75 80

Gly Gln Pro His Gly Gly Trp Gly Gln Gly Gly Thr His Asn  
 85 90 95

Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Leu Lys His Val Ala  
 100 105 110

Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met  
 115 120 125

Leu Gly Ser Ala Met Ser Arg Pro Met Ile His Phe Gly Asn Asp Trp  
 130 135 140

Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr Pro Asn Gln Val  
 145 150 155 160

Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His  
 165 170 175

Asp Cys Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr  
 180 185 190

Lys Gly Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg Val  
 195 200 205

Val Glu Gln Met Cys Val Thr Gln Tyr Gln Lys Glu Ser Gln Ala Tyr  
 210 215 220

Tyr Asp Gly Arg Arg Ser Ser Ser Thr Val Leu Phe Ser Ser Pro Pro  
 225 230 235 240

Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly  
 245 250

<210> 16  
<211> 8  
<212> PRT  
<213> **Mus musculus**

<400> 16

Gly Gly Gly Trp Gly Gln Pro His  
1 5

<210> 17  
<211> 8  
<212> PRT  
<213> **Mus musculus**

<400> 17

Gly Gly Ser Trp Gly Gln Pro His  
1 5

<210> 18  
<211> 20  
<212> DNA  
<213> **Artificial sequence**

<220>  
<223> **Synthetic oligonucleotide**

<400> 18  
tccatgacgt tcctgacgtt

20

<210> 19  
<211> 24  
<212> DNA  
<213> **Artificial sequence**

<220>  
<223> **Synthetic oligonucleotide**

<400> 19  
tcgtcggtt gtcgtttgt cgtt

24